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Abstract
Pre-diabetes is associated with impairments in cardiovascular health that manifest
prior to the onset of overt type 2 diabetes. Characterized by hyperinsulinemia and insulin
resistance, pre-diabetes has been associated with increases in sympathetic nerve activity,
which may result in augmented sympathetic control of the peripheral vasculature within
skeletal muscle. Currently however, there are no studies investigating the impact of prediabetes on sympathetically-mediated vascular control. The primary study of this thesis
investigated the effects of pre-diabetes on baseline sympathetic neuropeptide Y Y1 receptor
(NPY Y1R) and alpha 1 adrenergic receptor (α1R) control of hindlimb vascular tone.
Experiments were carried out in anesthetized pre-diabetic Zucker Diabetic Fatty (ZDF) rats
and control lean ZDF rats during drug delivery of sympathetic antagonists while measuring
femoral artery blood flow (Qfem) and calculated vascular conductance (VC). Despite similar
baseline Qfem and VC, Y1R, α1R and dual Y1R+α1R blockade (via BIBP3226 and
prazosin) elicited increases in Qfem and VC that were greater in pre-diabetic rats compared
to controls, demonstrating heightened Y1R and α1R control of baseline vascular tone. These
results were also supported by increased Y1R, α1R and NPY expression in hindlimb tissue
of pre-diabetic rats. In effort to determine whether pre-diabetes effects microvascular
network function in contracting skeletal muscle, intravital microscopy was used to evaluate
arteriolar rapid onset vasodilation (ROV) and steady-state vasodilation and blood flow
responses to tetanic and rhythmic contraction of the gluteus maximus muscle in pre-diabetic
(The Pound Mouse, c57bl6 background) and control mice (c57bl6). Baseline diameter and
blood flow of arterioles were similar between groups; however, contraction-evoked
vasodilatory and blood flow responses were blunted in pre-diabetic compared to control
ii

mice. In addition, the magnitude of contraction-evoked dilation was greater in distal
arterioles (3A and 4A) compared to proximal arterioles (2A) in GM arteriolar networks of
control mice; however, such spatially-dependent differences in contraction-evoked dilation
was disrupted in pre-diabetic mice. Blockade of Y1R and α1R (via BIBP3226 and prazosin)
restored ROV and steady-state vasodilation to tetanic and rhythmic contractions in prediabetic mice to levels similar to controls. Blockade of arteriolar sympathetic receptors also
restored dilatory magnitude of distal arterioles in pre-diabetic mice. In conclusion, the results
presented in this dissertation provide evidence that peripheral arteriolar Y1R and α1R
activation are enhanced in pre-diabetes, resulting in augmented sympathetic modulation of
basal skeletal muscle blood flow and VC, as well as deficits in arteriolar vasodilation to
skeletal muscle contraction.
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Chapter 1 : Introduction
1.1. General introduction
Pre-diabetes is characterized by elevated blood glucose and insulin resistance,
over-production of insulin and resultant hyperinsulinemia, affecting approximately 22%
of the Canadian population (Canadian Diabetes Association, 2011). Cardiovascular
disease, the most common diabetes-related co-morbidity, is prevalent in the pre-diabetic
state prior to the onset of overt type 2 diabetes (Faeh, William, Yerly, Paccaud, & Bovet,
2007; Haffner, Stern, Hazuda, Mitchell, & Patterson, 1990). In the peripheral vasculature,
specifically within skeletal muscle, compromised red blood cell (RBC) velocity and RBC
supply rates in capillaries have been demonstrated under basal conditions (Ellis et al.,
2010), suggesting functional deficits of upstream microvasculature. Skeletal muscle
comprises approximately 30-40% of total body mass (Janssen, Heymsfield, Baumgartner,
& Ross, 2000) and contains the largest proportion of the microvasculature responsible for
tissue blood flow distribution, i.e. arterioles. However little is known of the impact of
pre-diabetes on microvascular function within skeletal muscle.
Skeletal muscle microvasculature is comprised of arterioles, capillaries and
venules. The arterioles are arranged in a network spanning the tissue, and are integral to
distributing blood flow to the capillaries of active muscle fibers (via vasodilation) in an
effort to meet metabolic demand (Fronek & Zweifach, 1975; Mackie & Terjung, 1983;
Welsh & Segal, 1996). In contrast, concomitant arteriolar constriction in inactive tissues
occurs to maintain resistance throughout the arteriolar network and redirect blood flow to
sites of highest metabolic activity. Arteriolar constriction is achieved by the activation of
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peripheral sympathetic nerve fibers innervating skeletal muscle arterioles through the
release of sympathetic neurotransmitters (NT): norepinephrine (NE), neuropeptide Y
(NPY) and adenosine triphosphate (ATP). These neurotransmitters interact with their
respective sympathetic receptors (discussed in detail below) located on the arterioles to
elicit vasoconstriction.
Changes in sympathetic outflow are mediated by the arterial baroreflexes in an
effort to maintain overall systemic blood pressure on a moment-by-moment basis. The
arterial baroreceptors are mechanoreceptors or ‘stretch’ receptors located in the aortic
arch and carotid sinuses. Sudden increases or decreases in blood pressure deviating from
the ‘operating point’, activate or inhibit baroreceptor activity. For example, a decrease in
blood pressure elicits reciprocal increases in peripheral sympathetic outflow, causing
vasoconstriction of the resistance vasculature, increasing peripheral resistance, and
increasing blood pressure (Mosqueda-Garcia, 1996; Rowell, 1993). Under conditions of
work or exercise however, arteriolar vasodilation in response to skeletal muscle
contraction must occur to increase blood flow to the tissue, despite tonic arteriolar
sympathetic activation. Thus, any dysregulation of arteriolar sympathetic control could
deleteriously impact muscle microvascular supply at rest and under working conditions.
Although many diabetes-related vascular complications exist as a result of
hyperglycemia, hyperinsulinemia in pre-diabetes may contribute to microvascular
dysregulation, as insulin is known to stimulate sympathetic nerve activity (SNA). For
example, elevated SNA recordings using microneurography have been shown to correlate
with the degree of insulin resistance (E. A. Anderson, Balon, Hoffman, Sinkey, & Mark,
1992; DeFronzo & Ferrannini, 1991). Moreover, intracerebroventricular administration
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of insulin elicits increases in peripheral SNA (Muntzel, Anderson, Johnson, & Mark,
1995). Insulin has also been shown to stimulate muscle sympathetic nerve activity, and in
insulin resistant states, increased basal SNA has been reported (E. A. Anderson et al.,
1992; Berne, Fagius, Pollare, & Hjemdahl, 1992; Scherrer & Sartori, 1997). Interestingly,
insulin exerts its sympathoexcitatory effects selectively. In humans, insulin stimulates
increased SNA to skeletal muscle, but not to the skin, and in rats, insulin increases
lumbar sympathetic outflow, but not adrenal SNA (Berne et al., 1992; Morgan, Balon,
Ginsberg, & Mark, 1993). These findings may provide implications for peripheral
sympathetic dysregulation of arterioles within limb skeletal muscle in pre-diabetes.
The regulation of sympathetic receptor activation at the arterial level is integral in
maintaining resistance, tissue perfusion and blood pressure regulation at rest as well as
during periods of physical activity. Enhanced activation in diseased states, such as prediabetes, could lead to impairments in sufficient skeletal muscle perfusion. This could
occur via ‘hypersympathomodulation’ of skeletal muscle vasculature, where one or more
of the components involved in sympathetic vascular regulation are increased. This may
manifest as an increase in SNA, increased vascular sympathetic receptor expression, or
greater sympathetic neurotransmitter production and release. Studies investigating basal
sympathetic neurovascular control in the metabolic syndrome and obesity (conditions
possessing overlapping characteristics to pre-diabetes) have demonstrated heightened
alpha-adrenergic receptor (αR) contribution to basal vascular tone compared to lean
controls. It was shown that blockade of αR caused greater increases in iliac and femoral
vascular conductance (Frisbee, 2003; Naik, Xiang, Hodnett, & Hester, 2008), and that αR
activation of hindlimb arteries and cremasteric arterioles elicited greater vasoconstrictor
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responsiveness to adrenergic agonists (Naik et al., 2008; Stepp & Frisbee, 2002).
Although these past studies illustrate augmented adrenergic vascular regulation under
metabolic disease conditions, there is a paucity of studies that have investigated the
independent and/or interactive role of NPY under such conditions.
NPY is a 36 amino acid peptide that is co-stored with NE within peripheral
sympathetic nerves innervating skeletal muscle vasculature. It promotes potent and
prolonged arteriolar constriction through activation of the NPY Y1 receptor (Y1R). Past
studies have demonstrated that NPY is equally as important as NE in maintaining
arteriolar blood flow and vascular conductance under baseline conditions in male
Sprague Dawley rats (Jackson, Milne, Noble, & Shoemaker, 2005; Jackson, Noble, &
Shoemaker, 2004). The effects of NPY on microvascular tone were shown to be both
independent (via Y1R activation) (Jackson et al., 2004), and synergistic under conditions
of Y1R and alpha 1 adrenergic receptor (α1R) activation (Jackson et al., 2005). Neuronal
NPY release and its effects on arteriolar constriction become even more apparent under
conditions of elevated SNA (Bartfai, Iverfeldt, Fisone, & Serfozo, 1988; De Camilli &
Jahn, 1990; Lundberg, Franco-Cereceda, Lou, Modin, & Pernow, 1994). Thus, it is
reasonable to suspect that, under conditions of hyperinsulinemia and heightened baseline
SNA (i.e., in pre-diabetes), NPY and NE would promote vascular dysregulation under
baseline conditions, at the onset of exercise, and during steady state exercise.
Remarkably, there have been no studies investigating the roles of NPY and NE on
microvascular dysregulation pre-diabetes.
Under basal conditions, skeletal muscle is perfused with approximately 15% of
cardiac output. In contrast however, under high intensity exercise conditions, the
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proportion of cardiac output to working skeletal muscle can increase up to approximately
85% (Rowell, 1993), as increases in arteriolar diameter occur to increase blood flow to
the tissue. Chronic sympathetic hyperactivity, occurring with hyperinsulinemia in prediabetes, could therefore compromise blood flow to exercising muscle. Deficits in
skeletal muscle blood flow during exercise have indeed been reported in overt type 2
diabetes, metabolic syndrome and obesity in human and animal studies (Blain, Limberg,
Mortensen, & Schrage, 2012; Frisbee, 2004; Karpoff et al., 2009; Kingwell, Formosa,
Muhlmann, Bradley, & McConell, 2003; MacAnaney, Reilly, O'Shea, Egana, & Green,
2011; Vinet et al., 2011). Furthermore, enhanced arterial αR activation has been shown to
compromise contraction-evoked blood flow responses in the metabolic syndrome
(Frisbee, 2004). Such conclusions however, have been made based on hemodynamic
changes measured at large conduit arteries (e.g. brachial and femoral arteries) with the
use of Doppler ultrasound, venous occlusion plethysmography, transonic flow probes and
thermodilution, providing a summation of arterial responses downstream in the muscle
microvasculature. The large hyperemic response however is primarily encountered at the
level of the arterioles within the muscle itself, therefore inferences regarding sympathetic
vascular regulation, as well as dynamic changes of arteriolar diameter and blood flow in
response to muscle contraction must be made. In an effort to deduce where potential
sympathetic dysregulation within the arteriolar network occurs in the case of prediabetes, more invasive studies using animal models are needed.
Intravital studies of skeletal muscle microvasculature using animal models
provide the ability to directly observe the microcirculation and determine regulatory
mechanisms of blood flow within skeletal muscle. Stimulation of peripheral SNA has

6
shown to elicit variable vasoconstriction responses of arterioles depending on where they
lie within the arteriolar network (J. M. Marshall, 1982), where constriction responses of
smaller arterioles occurs to a greater extent compared to larger upstream arterioles
(Boegehold & Johnson, 1988; Folkow, Sonnenschein, & Wright, 1971; VanTeeffelen &
Segal, 2003). In an effort to drive capillary perfusion, distal arterioles have additionally
demonstrated a greater ability to ‘overcome’ sympathetic constrictor restraint via
vasodilation not only in resting, but also in active muscle (Folkow et al., 1971). Under
circumstances of heightened SNA however, skeletal muscle arterioles may be affected
differently depending on their location in the network. Therefore, in an effort to
investigate whether pre-diabetes affects sympathetic skeletal muscle vascular function at
the arteriolar level, an appropriate pre-diabetic model and skeletal muscle model for
microvascular investigation is needed.

1.2. Skeletal muscle microvasculature: The role of arterioles
The skeletal muscle microcirculation is arranged in a network of blood vessels in
order to continuously distribute blood flow throughout the tissue. Skeletal muscle blood
flow is closely matched to metabolic demand of the tissue, where local changes in blood
flow have been shown to occur specifically to fibers activated during muscle contraction
(Mackie & Terjung, 1983). Dynamic changes in blood flow, based on metabolic need,
occur as a result of changes in vessel diameter, particularly at the level of the arterioles.
The arteriolar network is initiated at the feed artery entering the tissue, which bifurcates
into daughter arterioles (termed first-order arterioles), giving rise to a branching arteriolar
network (second order, third order arterioles, etc.) prior to reaching the terminal
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arterioles, ultimately distributing RBCs and plasma to the capillaries. Arteriolar networks
provide the greatest resistance to blood flow and, due to their branching architecture
throughout the muscle and large capacity to constrict and dilate (Bevan, Halpern, &
Mulvany, 1991; Tuma, Duran, & Ley, 2008), are essential to blood flow regulation and
distribution of cardiac output.
The outer wall of arterioles consist of a layer of vascular smooth muscle cells
(VSMC) surrounded by the external lamina or adventitia (Rhodin, 1967). The VSMCs
are responsible for arteriolar contractility and can spatially control blood flow to capillary
units supplying skeletal muscle fibers (Fuglevand & Segal, 1997). In resting skeletal
muscle oxygen consumption is low, as is blood flow throughout the tissue. Reduced
muscle perfusion under basal conditions occurs as a result of partial constriction of the
resistance arterioles. The contractile properties of VSMCs maintaining basal arteriolar
diameter are under a variable state of active shortening, referred to as “vascular tone”
(Bevan et al., 1991; Rhodin, 1967). The contractile state of VSMCs is regulated by a
balance of both vasodilator and vasoconstrictor control mechanisms. At rest, the need for
vasodilation of skeletal muscle arterioles is rather low, however basal levels of putative
dilators are necessary to negate increases in arteriolar resistance and preserve tissue
perfusion in the face of partial arteriolar constriction. For example, nitric oxide (NO) and
prostanoids, i.e., prostacyclin and prostaglandin E2, have been implicated in the
regulation of basal vascular tone within skeletal muscle (de Wit, von Bismarck, & Pohl,
1993; Radegran & Saltin, 1999).
In contrast to vasodilator mechanisms maintaining basal skeletal muscle blood
flow, there are also vasoconstrictor influences maintaining the contractile state of
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VSMCs, or “basal vascular tone”. A large contributor to maintaining partial constriction
of arterioles is the sympathetic nervous system (SNS). The VSMC layer surrounding
skeletal muscle arterioles is densely innervated with perivascular sympathetic nerve
fibers that provide a constant outflow of sympathetic NTs. Sympathetic NTs interact with
respective

sympathetic

receptors

located

on

VSMCs,

eliciting

constitutive

vasoconstrictive restraint on the arterioles and therefore maintaining resistance
throughout the arteriolar network. Skeletal muscle is considered to have a high level of
basal ‘vascular tone’ as it comprises a large proportion of the body, housing a substantial
amount of the microvasculature, and therefore greatly influences basal blood pressure
maintenance. In instances where metabolic demand of skeletal muscle increases however,
such as during exercise, arterioles dilate to increase blood flow and support contractile
activity of skeletal muscle.

1.3. The sympathetic nervous system: Peripheral neurovascular
regulation
1.3.1.

Sympathetic neurotransmission
The SNS plays an essential role in blood pressure maintenance and redistribution

of blood flow during stress or exercise (Robertson, Biaggioni, Burnstock, Low, & Paton,
2012). Initiation of sympathetic outflow has been associated with central nervous system
areas within the brain/brainstem such as the ventromedial and rostral ventrolateral
medulla, caudal raphe nuclei, and paraventricular nucleus (Strack, Sawyer, Hughes, Platt,
& Loewy, 1989). From the brain, supraspinal neurons project to cell bodies within the
lateral horn of the spinal gray matter in the thoracolumbar spinal cord (T1-L2).
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Sympathetic cell bodies give rise to pre-ganglionic neurons that innervate postsympathetic neurons residing within the sympathetic ganglia (Robertson et al., 2012).
Activation (or deactivation) of sympathetic outflow from supraspinal brain centers occurs
on a moment-by-moment basis, entrained with the baroreflex (as discussed below), where
neuronal impulses are stimulated and traverse to pre-ganglionic neurons. Upon activation,
acetylcholine (ACh) is released from the pre-ganglionic neuron terminal, then binds to
and activates nicotinic receptors of the post-ganglionic neurons at the sympathetic
ganglion. Post-ganglionic neurons are unmyelinated and travel long distances, especially
to the vasculature of the lower limbs, from the presynaptic ganglia to reach target organs.
Excitatory impulses initiated by nicotinic receptor activation propagate along postganglionic nerve fibers to elicit exocytosis of vesicles containing NTs (Robertson et al.,
2012). Post-ganglionic fibers supplying the vasculature of the lower body (pertaining to
this thesis) originate from the lumbar and sacral paravertebral ganglia. These fibers come
together into small bundles, forming a plexus within the adventitia of arterioles. This
plexus then gives rise to a secondary plexus of fibers termed the terminal effector plexus,
that resides on the surface of the medial layer of the vessel, where nerve fibres are then
adjacent to the VSMCs (Robertson et al., 2012). The terminal effector plexus possesses
varicosities, which contain small and large-dense cored vesicles (SDCV and LDCV)
containing sympathetic NTs. These vesicles are generated near the golgi apparatus in the
cell bodies and move by axonal transport within the axons to the nerve terminals of the
terminal effector plexus. Sympathetic NT release from the vesicles is initiated by the
release of pre-ganglionic ACh from nerve terminals that interacts with post-ganglionic
nicotinic receptors, causing an increase in axon permeability to sodium. The increase in
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sodium causes the opening of voltage-gated calcium channels, causing an influx of
calcium, resulting in the fusion of vesicular and axonal membranes. The vesicle is then
able to release its contents into the extracellular space close to the VSMCs, where NTs
then interact with respective receptors located on the VSMCs, ultimately causing
vasoconstriction (Robertson et al., 2012). For the purposes of this thesis, NE and NPYmediated regulation of skeletal muscle vasculature will be addressed.

1.3.2.

Norepinephrine
NE is the classically studied catecholamine involved in sympathetic vascular

regulation. NE is found within adrenergic neurons, as well as in the chromaffin cells of
the adrenal gland. Catecholamine synthesis begins with the uptake of the amino acid
tyrosine into the cytoplasm of sympathetic neurons. Tyrosine hydroxylase, the rate
limiting enzyme in the production of NE, then catalyses the conversion of tyrosine to
dihydroxyphenyl-alanine. Dihydroxylphenyl-alanine is then converted to dopamine by
the enzyme dopamine-decarboxylase. The aforementioned steps occur in the cytoplasm
of the neuron, however dopamine-beta-hydroxylase catalyzes the conversion of dopamine
to NE within the vesicles themselves. Once vesicles release NE into the extracellular
space, NE interacts with respective αR and beta-adrenergic receptors (βR) located on the
VSMCs. Binding of NE to the α1R and alpha 2 adrenergic receptor (α2R) causes
calcium release from the sarcoplasmic reticulum within VSMCs, as well as increases
VSMC membrane permeability to calcium. Increased intracellular calcium activates the
calcium-calmodulin complex to cause VSMC constriction (Webb, 2003). Beta 2
adrenergic receptors (β2R) are also present along VSMCs within skeletal muscle, which
when activated by agonists such as isoproteranol, cause arteriolar vasodilation. Once the
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β2R is activated, production of intracellular cyclic adenosine monophosphate (cAMP)
can inhibit calcium release from the sarcoplasmic reticulum and calcium entry into the
cell, causing VSMC relaxation (Johnson, 2006). The effects of NE on β2R activation are
not resolvable unless the vasoconstrictor effects of α1R and α2R are blocked (Cowley &
Franchini, 1996), demonstrating the predominant effect of NE on αR activation. Once
NE disassociates from the respective receptor, it is inactivated by re-uptake via the
Uptake-1 transporter into the axoplasm of the neuron where it can be stored into vesicles
for future release or metabolized (Robertson et al., 2012). For the purposes of this thesis,
focus will be on the α1R.

1.3.2.1.

Alpha 1 adrenergic receptor

Alpha 1 adrenergic receptors are long single-chain membrane-integrated
glycoproteins and members of the G protein-coupled receptor superfamily. The receptor
contains seven transmembrane alpha-helical domains, possessing three intracellular and
three extracellular loops, and an intracellular juxtamembranous portion forming the
eighth alpha-helix. The N-terminus of the receptor lies on the extracellular surface, where
the C-terminus is located on the intracellular surface. Upon binding of NE to the receptor,
G q-protein activation then activates second messenger protein pathways that contribute
α

to increasing intracellular VSMC calcium levels (Robertson et al., 2012). G q-protein
α

activation stimulates the activity of phospholipase C to hydrolyze phosphatidylinositolbis-phosphate into inositol 1,4,5-triphosphate (IP3) and diacylglycerol. IP3 can directly
initiate calcium signaling, as it interacts with calcium release channels on the
sarcoplasmcic reticulum (SR) (Somlyo & Somlyo, 2000). Increased calcium in the
VSMC cytoplasm can also elicit calcium-induced calcium release from the SR, as well as
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activate extracellular calcium entry through L-type calcium channels on the cell
membrane (Hawrylyshyn, Michelotti, Coge, Guenin, & Schwinn, 2004; Wier & Morgan,
2003). Calcium binds to calmodulin, creating the calcium-calmodulin complex. This then
activates myosin light chain kinase which phosphorylates myosin light chain, causing
myosin cross-bridge activation and VSMC contraction (Wier & Morgan, 2003).
Endogenous α1R regulation of the vasculature in this thesis was determined with
the highly selective α1R antagonist prazosin (2-[4-(2-furoyl)- piperazin-l-yl]-4-amino6,7-dimethoxyquinazolhinyedrochloride). Prazosin elicits hypotensive and vasodilatory
effects by blocking the interaction between NE and the α1R, and therefore interfering
with sympathetically-activated VSMC contraction (Graham, Oates, Stoker, & Stokes,
1977; Oates, Graham, Stoker, & Stokes, 1976). Interestingly, the actions of prazosin have
been predominantly identified at the level of the peripheral vasculature, where tissue
distribution studies have also confirmed the majority of drug localization to the arterioles
(Hess, 1975).

1.3.3.

Neuropeptide Y
NPY is a 36 amino acid peptide that is co-stored and released with NE from

peripheral sympathetic neurons (Ekblad et al., 1984). NPY was first isolated from the
porcine brain (Tatemoto, Carlquist, & Mutt, 1982), and occurs abundantly in the
mammalian central nervous system, as well as in the peripheral nervous system
(Wahlestedt et al., 1990). Its composition is well conserved and is part of a family that
includes peptide YY and pancreatic polypeptide. It is originally derived from a 97 amino
acid precursor, pre-pro-NPY. Four post-translational enzymatic modifications follow in
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order to synthesize the biologically active NPY1-36. Prohormone convertase 1/3 cleaves
proNPY, releasing a 30 amino acid c-flanking peptide of pre-proNPY and NPY

1-39

(Alfalah & Michel, 2004). Two amino acids of NPY1-39 are then cleaved by a
carboxypeptidase-like enzyme to form NPY1-37. Finally, NPY1-37 is amidated at its Cterminal by peptidyl-glycine-α-amidating monooxygenase to form the final biologically
active peptide NPY1-36. In the peripheral SNS, it is stored in post-ganglionic sympathetic
neurons that innervate blood vessels, however NPY-containing neurons have been shown
to be more abundant around resistance arterioles and proceed to innervate vessels in
higher density as the arteriolar tree diverges into terminal branches (Sundler, Bottcher,
Ekblad, & Hakanson, 1993). Although NPY is co-stored with NE, NPY is contained
within LDCV of post-ganglionic sympathetic neurons, as opposed to SDCV that
generally house NE. NPY release from these vesicles has been shown to occur to a
greater extent under higher neuronal stimulation frequencies, however studies have
confirmed that NPY is also released under lower stimulation frequencies (De Potter,
Partoens, Schoups, Llona, & Coen, 1997), and is able to elicit vasoconstrictive effects
under resting basal conditions (Bartfai et al., 1988; Jackson et al., 2004; Lundberg et al.,
1994). When NPY is released from these neurons, it acts on its respective Y1R to cause
potent and prolonged vasoconstriction, a phenomenon initially discovered in cat skeletal
muscle (Ekelund & Erlinge, 1997). NPY is degraded by enzymes dipeptidyl peptidase IV
(DPPIV) to generate NPY3-36, and amino peptidase P (APP) to generate NPY2-36. DPPIV
is a membrane-bound protease found on the cells of kidneys, liver, ileum, and also on
endothelial cells, epithelial cells, astrocytes and T and B lymphocytes (Stange, Kettmann,
& Holzhausen, 1996). It cleaves proline at the penultimate position, removing the tyr-pro
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dipeptide from the N-terminus of NPY1-36, generating NPY3-36, which has less affinity for
the Y1R (Grandt et al., 1993; Hopsu-Havu & Glenner, 1966). APP is found on astrocytes,
endothelial cells, epithelial cells, neuronal cells and lung cells, and cleaves residues at the
N-terminal to create NPY2-36, also decreasing the affinity to Y1R binding.

1.3.3.1.

Neuropeptide Y Y1 receptor

The NPY Y1R was the first NPY receptor identified and cloned from the rat
cDNA library, having 90-96% overall identity across mammals (Eva, Keinanen, Monyer,
Seeburg, & Sprengel, 1990; Larhammar et al., 1992). NPY Y1R expression has been
detected in the brain, heart, kidneys, the gastrointestinal tract and skeletal muscle.
Importantly, Y1Rs are located peripherally on arterioles where they mediate
vasoconstrictive responses (Grundemar & Bloom, 1994). NPY Y1R is a G-protein
coupled receptor. It is characterized by 7 trans-membrane spanning domains linked to a
heterotrimeric Gi/o-protein. Activation of Y1R is specific to the full NPY1-36 peptide.
Truncated analogues of NPY at the N- and C-terminus, as well as modifications of
central segments of the peptide result in significant decreases in NPY Y1R receptor
affinity (Beck-Sickinger & Jung, 1995; Danho et al., 1988). The C-terminal region of
NPY plays a main role in Y1R recognition as modifications to this end results in the
greatest reductions in receptor affinity (Hoffmann, Rist, Videnov, Jung, & BeckSickinger, 1996). When NPY Y1R is activated, increases in intracellular calcium causes
slow and long lasting depolarization of smooth muscle cells to elicit vasoconstriction
(Dumont, Martel, Fournier, St-Pierre, & Quirion, 1992). Studies have reported that NPY
can increase intracellular calcium via inhibition of ATP-sensitive potassium channels,
activation of voltage-gated calcium channels and the inhibition of cAMP (Edvinsson,
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1985; Edvinsson, Emson, McCulloch, Tatemoto, & Uddman, 1983; Motulsky & Michel,
1988; Tanaka et al., 1995). In support, NPY-induced vascular smooth muscle cell
contraction can be inhibited by calcium channel antagonists (Lundberg et al., 1985).
In order to determine the endogenous Y1R-mediated effects of NPY on the
vasculature,

N2-(diphenylacetyl)-N-[(4-hydroxyphenyl)-methyl]-D-arginine

amide

(BIBP3226) was used in the studies described in this thesis. BIBP3226 is a highly potent
and selective non-peptide Y1R antagonist, sharing similar Y1R molecular binding sites to
NPY (Grundemar & Bloom, 1994). Past in vivo work in the rat has confirmed the ability
of BIBP3226 to block the hypertensive response elicited by intravenous administration of
NPY (Doods et al., 1995) and NPY induced vasoconstriction in rat skeletal muscle
(Jackson et al., 2005).

1.3.4.

Interactions between NPY and NE
Sympathetic postganglionic neurons release NE, NPY and ATP (Kasakov, Ellis,

Kirkpatrick, Milner, & Burnstock, 1988). The release of each of these NTs can be
modified as levels of SNA changes, allowing for a number of biological effects and
interactions (e.g. slow, intermediary, and quick signaling) (Lundberg, 1996). For
example, NPY produces a slow acting, potent and persistent increase in vascular tone. In
contrast, NE-induced vasoconstriction occurs quickly and decays at a similar rate.
Moreover, ATP induced vasoconstriction has been shown to be immediate and very short
acting. It has been postulated that the duration of each transmitter’s effects relies on the
mode of deactivation/removal. For example, NE’s vascular effects are removed quickly
(NE reuptake via Uptake-1) compared to the prolonged duration of NPY induced
vasoconstriction that is eliminated by enzymatic degradation of “free” NPY by DPPIV
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and APP (Lundberg, 1996). In several investigations, NPY has been shown to potentiate
α-adrenergic vasoconstriction in vivo (Dahlof, Dahlof, & Lundberg, 1985; Jackson et al.,
2005; Linder, Lautenschlager, & Haefeli, 1996; Revington & McCloskey, 1988), as well
as in vitro (Edvinsson, Ekblad, Hakanson, & Wahlestedt, 1984; Ekblad et al., 1984;
Glover, 1985; Wahlestedt, Edvinsson, Ekblad, & Hakanson, 1985). The synergistic
interaction between NPY and NE is receptor-mediated, as NPY has also been shown to
enhance the vasoconstrictive response to sympathetic nerve stimulation and
phenylephrine- (specific α1R agonist) induced vasoconstriction (Dahlof et al., 1985).
Additionally, NPYs endogenous contribution to basal vascular tone has been shown to
act synergistically with endogenous NE. Upon simultaneous blockade of Y1R and α1R
of the hindlimb vasculature in male Sprague-Dawley rats, the increase in femoral artery
vascular conductance was greater then the additive response elicited by independent
blockade of each receptor (Jackson et al., 2004). It has been hypothesized that the
interactive effects between Y1R and α1R are due to consequent modification of specific
receptor properties and/or second messengers (Franco-Cereceda & Liska, 1998). Both
Y1R and α1R are G-protein coupled receptors; therefore, cross talk between receptormediated changes in downstream signaling events may occur. Interestingly, the
potentiating effects of NPY requires increased phospholipase C activity, which may
further mobilize intracellular calcium (Wahlestedt et al., 1985; Wahlestedt et al., 1990).
In addition, NPY may also inhibit adenyl cyclase upon Y1R activation, decreasing
downstream levels of cAMP (Kassis, Olasmaa, Terenius, & Fishman, 1987), thus
reducing the relaxing effects of cAMP. Exact mechanisms behind potentiating efffects of
NPY however are not completely understood.
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1.4. Skeletal muscle contraction, functional hyperemia and
sympatholysis
Under basal conditions, there is a constant balance between arteriolar sympathetic
activation and local vasodilator mechanisms (vascular tone). Increases in metabolic
demand however elicits vasodilation of arterioles to increase blood flow to the working
tissue and throughout the downstream capillary network – termed functional or exercise
hyperemia (Bevan et al., 1991; Laughlin, Korthuis, Duncker, & Bache, 1996). Dilation of
distal or terminal arterioles serving capillary units closest to activated muscle fibers
initiates increases in blood supply, where modest adjustments of feed artery and proximal
arteriole diameter occur. However in cases of intense exercise, muscle blood flow can
increase up to 100-fold, constituting up to 90% of cardiac output (Saltin, Radegran,
Koskolou, & Roach, 1998). High-intensity exercise elicits large vasodilatory responses
within skeletal muscle, therefore providing an opportunity for large drops in arterial
blood pressure (R. J. Marshall, Schirger, & Shepherd, 1961). To prevent a fall in blood
pressure, SNA is increased (Rowell, 1993) as a result of the baroreflex. Heightened
peripheral SNA therefore increases vasoconstrictor activity of the feed artery, proximal
arterioles, and dilated terminal arterioles to maintain resistance throughout the arteriolar
network of working tissue, as well as increase vasoconstriction to inactive tissues
(Thomas & Segal, 2004). Increases in perivascular SNA has also been shown to
suppresses conducted vasodilatory responses along skeletal muscle arterioles (Haug &
Segal, 2005). The ability of arterioles to dilate, regardless of increased sympathetic
neurovascular activation during exercise however, is termed ‘functional sympatholysis’
(Hansen, Sander, & Thomas, 2000; Remensnyder, Mitchell, & Sarnoff, 1962).
Sympathetically-mediated skeletal muscle arteriolar constriction is greater at smaller
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terminal arterioles feeding capillary units (J. M. Marshall, 1982); however, these
arterioles have also been shown to undergo sympatholysis more readily compared to
upstream vasculature during exercise (Folkow et al., 1971). Under such conditions,
functional sympatholysis promotes distal arteriolar dilation to maximize perfusion of
capillary networks supplying active muscle fibres (Folkow et al., 1971; Segal & Jackson,
2005). In diseased states where hypersympathomodulation of skeletal muscle vasculature
occurs, such as pre-diabetes (Novielli, Al-Khazraji, Medeiros, Goldman, & Jackson,
2012), skeletal muscle arteriolar perfusion may become compromised as sympatholysis
may occur to a lesser extent, especially in distal arterioles experiencing pronounced
sympathetic vasoconstriction. Increased SNA has been confirmed in aged humans, and
has been shown to reduce muscle blood flow at rest and during exercise (Dinenno, Jones,
Seals, & Tanaka, 1999). More recently, this deficit in muscle blood flow has been
attributed to hyperactivation of adrenergic receptors in aged animal models and humans
(Casey & Joyner, 2012; Jackson, Moore, & Segal, 2010). Whether greater activation of
sympathetic receptors (adrenergic and non-adrenergic) compromises arteriolar function
and muscle blood flow in pre-diabetes remains to be investigated.

1.5. Pre-diabetes and vascular dysregulation
Pre-diabetes represents the initial stage of type 2 diabetic disease development,
characterized by insulin resistance and elevated circulating insulin and glucose levels. As
insulin resistance decreases tissue sensitivity to insulin, an overproduction of insulin
results to promote glucose uptake and maintain near-normal blood glucose levels. Prediabetic disease progression to overt type 2 diabetes occurs when pancreatic beta cells
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can no produce insulin to overcome insulin resistance, resulting in further hyperglycemia
(Bock et al., 2006; Dinneen et al., 1998; Kanauchi, Kanauchi, Inoue, Kimura, & Saito,
2007; Meigs, Muller, Nathan, Blake, & Andres, 2003; Tirosh et al., 2005). Such
pathological metabolic characteristics of pre-diabetes play a role in the initiation of
cardiovascular complications that manifest prior to the onset of overt type 2 diabetes
(Faeh et al., 2007; Gupta et al., 2012; Haffner et al., 1990; Schaefer et al., 2010; Shin,
Lee, & Lee, 2011). Increased femoral intima media thickness, elevated blood pressure,
augmented brachial-ankle pulse wave velocity, and impaired reperfusion hyperemia of
the fingers have been reported in pre-diabetic humans, however there is a dearth of
knowledge regarding the effects of pre-diabetes on microvascular function within skeletal
muscle.
Although few, past studies have addressed modifications in arteriolar function as
well as skeletal muscle capillary perfusion in pre-diabetic rats. Lesniewski et al. reported
increases in vasoconstrictor responsiveness to NE and endothelin-1 in first order
arterioles isolated from the gastrocnemius of normotensive pre-diabetic Zucker Diabetic
Fatty (ZDF) rats (Lesniewski et al., 2008). In addition to pro-constrictor phenotypes of
skeletal muscle arterioles, Ellis et al. demonstrated decreased RBC supply rate and
decreased RBC velocity in capillary networks of the extensor digitorum longus muscle of
the pre-diabetic ZDF rat (Ellis et al., 2010). These studies have demonstrated augmented
arteriolar function of proximal arterioles and impaired capillary perfusion of skeletal
muscle in early pre-diabetes; thus, it is reasonable to postulate that compromised
arteriolar function occurs throughout the skeletal muscle microvascular network.
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Studies directly investigating the impact of pre-diabetes on skeletal muscle
microvascular control during exercise are limited. Certainly, human and animal studies
have illustrated compromised blood flow regulation during exercise/muscle contraction
in overt type 2 diabetes, the metabolic syndrome, and obesity (Blain et al., 2012, Vinet et
al., 2011, Karpoff et al., 2009, Frisbee, 2003, Frisbee, 2004, MacAnaney et al., 2011,
Kingwell et al., 2003). However, differences in the experimental models and
methodological limitations constrain the current understanding of vascular control in
metabolic diseases to bulk blood flow measures, i.e. femoral or brachial artery blood
flow. Measures of bulk blood flow limits information on the site or nature of arteriolar
dysregulation. Intravital techniques would be advantageous for directly addressing the
microvascular network. Furthermore, models of overt type 2 diabetes, metabolic
syndrome, and obesity are accompanied by chronic states of cardiovascular compromise
and overt vascular disease; where early pre-diabetes represents the primary stage of
diabetic disease, where vascular complications may not be as pronounced.

1.6. Animal models of pre-diabetes
1.6.1.

The Zucker Diabetic Fatty rat
The ability to directly assess the effects of pre-diabetes on skeletal muscle

vasculature can be performed using pre-diabetic animal models. The ZDF rat represents a
model of progressive type 2 diabetes development. The ZDF rat has a genetic mutation of
the leptin receptor, interrupting the interaction of leptin with its respective receptor.
Leptin, a small adipose-derived hormone, is involved in the regulation of food intake via
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a negative feedback loop upon binding to the leptin receptor (Clement et al., 1998;
Lyssenko et al., 2005). Because of the dysfunctional leptin receptor in the ZDF rat, leptin
is unable to signal cessation of food intake. When fed a high fat diet, the ZDF rat
progressively develops programmed and consistent type 2 diabetes by the age of 8-9
weeks old. During the period prior overt type 2 diabetes development and pancreatic
failure, the rat is considered to be in the pre-diabetic state. At 7-weeks-old, the ZDF rat
demonstrates similar characteristics to the human condition of pre-diabetes; obesity,
hyperinsulinemia, insulin resistance and elevated blood glucose –(Kim & Reaven, 2008;
Lyssenko et al., 2005).

1.6.2.

The Pound Mouse
Similar to the ZDF rat, the pound mouse also expresses a dysfunctional leptin

receptor, in turn causing hyperphagia. The pound mouse is of the c57blk background and
occurred as a spontaneous mutation at a Charles River facility. When fed a high fat diet,
these mice exhibit obesity, hyperinsulinemia, insulin resistance and elevated blood
glucose, similar to the pre-diabetic characteristics outlined for the human pre-diabetic
condition. Unlike the ZDF rat however, the pound mouse does not go on to develop type
2 diabetes and pancreatic failure, rather it remains in a pre-diabetic state.

1.7. Rationale
Sympathetic neurovascular control is essential to the regulation of blood pressure
and tissue perfusion due to its ability to modulate peripheral vascular resistance. It is
especially important throughout skeletal muscle microvasculature, as skeletal muscle
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makes up approximately 40% of body mass and comprises approximately 20% of total
peripheral resistance under baseline conditions. NTs such as NE and NPY are released
from perivascular nerve terminals and act post-junctionally on VSMC α1Rs and Y1Rs to
produce vasoconstriction. In states where peripheral sympathetic activation may be
elevated, such as pre-diabetes, heightened sympathetic neurovascular modulation may
result, leading to compromised skeletal muscle vascular control.
In pre-diabetes, SNA is suggested to be elevated, as hyperinsulinemia
accompanying the disease is known to be sympathoexcitatory (E. A. Anderson et al.,
1992; E. A. Anderson, Hoffman, Balon, Sinkey, & Mark, 1991; Rowe et al., 1981). In
humans, hyperinsulinemia is associated with elevated SNA and correlates with the degree
of insulin resistance (E. A. Anderson et al., 1992; DeFronzo & Ferrannini, 1991; Huggett,
Hogarth, Mackintosh, & Mary, 2006). Moreover, systemic infusion of insulin in rats has
been shown to preferentially increase lumbar SNA (Epstein & Sowers, 1992; Esler et al.,
2001; Muntzel et al., 1995; Scherrer & Sartori, 1997). Increases in peripheral SNA
accompanying pre-diabetes may therefore compromise skeletal muscle microvascular
regulation under resting and active conditions via over-activation of arteriolar
sympathetic receptors, however this is yet to be investigated.
Indeed studies investigating skeletal muscle vascular function under conditions of
ageing, the metabolic syndrome and obesity have demonstrated increased basal vascular
tone and compromised vasodilation of skeletal muscle vasculature as a result of
heightened sympathetic vascular control (Casey & Joyner, 2012; Frisbee, 2004; Jackson
et al., 2010; Naik et al., 2008). Such studies have only evaluated the contribution of αR
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activation to sympathetically-mediated changes in vascular function; however,
peptidergic NPY Y1R vascular control has not been considered. Under conditions of
elevated SNA, sympathetic vascular modulation becomes more pronounced not only by
NE-, but also NPY (Bartfai et al., 1988; De Camilli & Jahn, 1990; Lundberg et al., 1994).
This provides implications for heightened adrenergic and peptidergic modulation of the
vasculature in pre-diabetes, which may affect basal sympathetic vascular tone, as well as
impinge on dilatory responses to skeletal muscle contraction.
Microvascular responses to skeletal muscle contraction are non-uniform
throughout the arteriolar network, with greater (relative) arteriolar dilation occurring in
distal versus proximal regions (Davis, Hill, & Kuo, 2008; Dodd & Johnson, 1991; J. M.
Marshall & Tandon, 1984; VanTeeffelen & Segal, 2006). Distal arterioles are also able to
dilate and overcome sympathetic activation (sympatholysis) more readily than proximal
arterioles within the muscle (K. M. Anderson & Faber, 1991). Interestingly, studies have
demonstrated differential distribution of sympathetic receptors at different arteriolar
branch orders of arteriolar networks (K. M. Anderson & Faber, 1991; Moore et al., 2010).
Furthermore, NPY-containing perivascular neurons have been shown to be more
abundant around resistance arterioles and innervate distal arterioles of the microvascular
network in higher density (Sundler et al., 1993). Under conditions of heightened SNA,
i.e. in pre-diabetes, such distinct spatial sympathetic arteriolar control may be lost, where
vasodilatory responses to skeletal muscle contraction may be compromised. Therefore,
direct investigation of both adrenergic and peptidergic-mediated arteriolar network
control is needed to address whether elevated SNA contributes to decrements in skeletal
muscle microvascular function in pre-diabetes.
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1.8. Specific thesis objectives
The overall objectives of this thesis research are the following:
Objective 1 – Manuscript 1: Chapter 2
To address whether basal endogenous Y1R and α1R regulation of hindlimb vasculature is
modified in pre-diabetic ZDF rats.
Objective 2 – Manuscript 2: Chapter 3
To establish and characterize the Pound mouse (pre-diabetic mouse model) and gluteus
maximus muscle preparation as appropriate in vivo models to study skeletal muscle
arteriolar function in pre-diabetes.
Objective 3 – Manuscript 2: Chapter 3
To determine whether pre-diabetes affects arteriolar vasodilation and blood flow
responses to skeletal muscle contraction across arteriolar branches throughout the gluteus
maximus microvascular network.
Objective 4 – Manuscript 3: Chapter 4
To determine if enhanced activation of sympathetic Y1R and α1R affects arteriolar
vasodilatory responses to muscle contraction in pre-diabetes.
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1.9. Hypotheses
Overall hypothesis: Sympathetic vascular modulation is elevated in pre-diabetes.
Hypothesis 1: Endogenous Y1R and α1R basal regulation of skeletal muscle vascular
tone is greater in pre-diabetes compared to healthy controls.
Hypothesis 2: Arteriolar vasodilation and blood flow responses elicited by contraction of
the gluteus maximus will be compromised in pre-diabetes compared to responses of
healthy controls, where the greatest decrements in contraction-evoked vasodilation will
occur in distal pre-capillary arterioles versus proximal arterioles.
Hypothesis 3: Blunted vasodilatory responses to gluteus maximus contraction observed in
pre-diabetes are a result of an elevation in basal arteriolar smooth muscle cell activation
of sympathetic arteriolar Y1R and α1R.
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2.1. Introduction
In the peripheral vasculature, sympathetic neurons regulate arteriolar tone through
the release of norepinephrine (NE) and neuropeptide Y (NPY). NE has been considered
the primary neurotransmitter in maintenance of baseline arteriolar tone (Z. ZukowskaGrojec, 1995) through its interaction with alpha-adrenergic receptors (αR) located on
vascular smooth muscle cells, causing vasoconstriction. NPY is co-stored and co-released
with NE and acts on neuropeptide Y1 receptors (Y1R), to cause potent and prolonged
vasoconstriction (Ekelund & Erlinge, 1997; Malmstrom, 1997; Z. Zukowska-Grojec &
Wahlestedt, 1993). Interestingly, post-synaptic co-activation of Y1R and α1R by NPY
and NE leads to synergistic vasoconstrictive effects (Z. Zukowska-Grojec & Wahlestedt,
1993). Although recent evidence has shown that NPY contributes modestly to baseline
vascular tone in skeletal muscle of male rats (Jackson, Noble, & Shoemaker, 2004), its
effects are suggested to predominate under conditions of elevated sympathetic nerve
activity (Bartfai, Iverfeldt, Fisone, & Serfozo, 1988; De Camilli & Jahn, 1990; Lundberg,
Franco-Cereceda, Lou, Modin, & Pernow, 1994).
A large proportion of the body’s resistance vasculature lies within skeletal
muscle, which is highly regulated by sympathetic nerve activity (SNA) to maintain blood
pressure and blood flow distribution under healthy conditions. However, in type 2
diabetes, sympathetic regulation of vascular tone can become augmented, leading to
alterations in normal blood flow control. Type 2 diabetes is commonly associated with
vascular disease; however, recent findings indicate that cardiovascular complications may
be initiated in the pre-diabetic state, before the diagnosis of type 2 diabetes (Faeh,
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William, Yerly, Paccaud, & Bovet, 2007; Haffner, Stern, Hazuda, Mitchell, & Patterson,
1990). Pre-diabetes is characterized by the concomitant presence of hyperinsulinemia,
impaired glucose tolerance and insulin resistance and occurs prior to overt pancreatic βcell failure. Of note, hyperinsulinemia stimulates SNA and may play a role in autonomic
and vascular dysfunction associated with the disease (Mancia, Grassi, Giannattasio, &
Seravalle, 1999). In humans, hyperinsulinemia is associated with elevated SNA and
correlates with the degree of insulin resistance (Anderson, Balon, Hoffman, Sinkey, &
Mark, 1992; DeFronzo & Ferrannini, 1991; Huggett, Hogarth, Mackintosh, & Mary,
2006). Moreover, systemic infusion of insulin in rats has been shown to preferentially
increase lumbar SNA (Epstein & Sowers, 1992; Esler et al., 2001; Muntzel, Anderson,
Johnson, & Mark, 1995; Scherrer & Sartori, 1997). Studies using animal models of prediabetes and the metabolic syndrome have reported augmented α-adrenergic vascular
responsiveness to adrenergic agonists in isolated vascular preparations (Lesniewski et al.,
2008; Okon, Szado, Laher, McManus, & van Breemen, 2003). As noted above, NPYmediated vascular modulation becomes more pronounced under conditions of elevated
SNA (Bartfai et al., 1988; De Camilli & Jahn, 1990; Lundberg et al., 1994); however, to
date, studies addressing NPY/Y1R-mediated vascular control in pre-diabetes are lacking.
Furthermore, there have been no studies investigating NPY and α-adrenergic comodulation of vascular control in pre-diabetes.
The overall aim of the present study was to investigate if pre-diabetes modifies
sympathetic Y1R and α1R control of basal skeletal muscle blood flow (Qfem) and
vascular conductance (VC). Thus, we tested the independent and dependent (synergistic)
functional contributions of endogenous Y1R and α1R activation on Qfem and VC in vivo
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and hypothesized that pre-diabetes augments Y1R and α1R vascular modulation.
Concurrently, we hypothesized that skeletal muscle NPY concentration and Y1R and
α1R expression would be upregulated in pre-diabetic rats.

2.2.

Materials and methods

All animal procedures were approved by the Council on Animal Care at The
University of Western Ontario (protocol number: 2008-066). All invasive procedures
were performed under α-chloralose and urethane anesthetic, and all efforts were made to
minimize animal suffering.

2.2.1.

Animals
Nine seven-week-old male ZDF rats (PD) and 8 age-matched lean controls

(CTRL) (Charles River Laboratories, Saint-Constant, Quebec, Canada) were used in this
study. The inbred ZDF rat is affected by a homozygous mutation of the leptin receptor
(fa/fa), therefore leptin is unable to suppress appetite (Leonard, Watson, Loomes,
Phillips, & Cooper, 2005). When fed a high fat diet (i.e., Purina 5008 rat chow), these
animals become obese, hyperinsulinemic, insulin resistant and hyperglycemic by 7 weeks
of age (Leonard et al., 2005; Lesniewski et al., 2008), characteristic of the pre-diabetic
condition in humans (Kim & Reaven, 2008a, 2008b). This phenotype is absent in the
ZDF lean rats heterozygous for the leptin receptor mutation (fa/+), and thus served as the
control group in this study. Animals were housed in animal care facilities in a
temperature (24°C) and light (12-hour cycle)-controlled room, fed Purina 5008 rat chow
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(Ralston Purina, St. Louis, MO, USA) and allowed to eat and drink water ad libitum.
Prior to surgery, animals were anesthetized with an intraperitoneal injection of αchloralose (80 mg/kg) and urethane (500 mg/kg). This anesthetic was ideal for this study
as it leaves autonomic, cardiovascular and respiratory function intact (Soma, 1983).
Internal body temperature was monitored via a rectal temperature probe and maintained
at 37°C with the use of a thermally controlled water-perfused heating pad.

2.2.2.

Surgery
A mid-neck incision was made and a tracheal cannula was introduced to facilitate

spontaneous respiration. End-tidal CO2 and O2 measures were made from expired air
between pharmacological perturbations throughout the experiment using a breath-bybreath gas analyzer (ADInstruments, Colorado Springs, CO, USA). The left common
carotid artery was cannulated (PE-50 tubing) to allow for recording of arterial blood
pressure via the amplified signal of a pressure transducer using a PowerLab system
(model ML118 PowerLab Quad Bridge Amplifier; model MLT0699 BP Transducer,
ADInstruments, Colorado Springs, CO, USA). The right jugular vein was cannulated to
maintain a constant infusion of anesthetic to the animal (α-chloralose: 8-16 mg/kg/hr,
urethane: 50-100 mg/kg/hr).
Through a midline abdominal incision, gut contents were carefully moved aside
within the abdominal cavity and covered with sterile gauze moistened with sterile saline
(0.9% NaCl). Sterile cotton swabs were then used to expose the descending aorta and
right iliac artery, isolating it from the right iliac vein and its surrounding fat. The right
iliac artery was cannulated (PE-50 tubing) and the cannula was advanced to the
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bifurcation of the descending aorta. This cannula was used for localized drug delivery to
the left hindlimb. Following cannulation, gauze was removed and care was taken to
reposition the gut. Incisions were closed with sterile wound clips (9 mm stainless steel
wound clips). A blood sample was then taken from the carotid cannula in order to
evaluate blood glucose levels, lactate levels, and pH using an iSTAT portable clinical
analyzer (Abbott Laboratories, Abbott Park, IL, USA).
Using microscopic assistance, the left femoral artery was carefully isolated from
surrounding nerves and vessels. Qfem was measured beat-by-beat using a Transonic flow
probe (0.7 PSB) and flowmeter (model TS420 Perivascular Flowmeter Module;
Transonic Systems, Ithica, NY, USA). The flow probe was placed around the left femoral
artery ~3 mm from the femoral triangle and innocuous water-soluble ultrasound gel was
applied over the opened area of the left hindlimb to keep tissue hydrated and to maintain
adequate flow signal.

2.2.3.

Experimental protocol
Once surgery was completed, animals recovered for 1 hour. Prior to drug

treatments, vehicle (160 µl of 0.9% saline) was delivered, followed by a 15-minute
recovery period. Baseline data were recorded for 5 minutes followed by five separate
drug infusions (Jackson, Ellis, & Shoemaker, 2010; Jackson, Milne, Noble, &
Shoemaker, 2005a, 2005b; Jackson et al., 2004). Using a repeated measures design, drug
infusions were delivered at a rate of 16 µl/sec in the following order: 1) 250 µl of 0.2
µg/kg acetylcholine chloride (ACh, Sigma-Aldrich, St. Louis, MO, USA), 2) 160 µl of
100 µg/kg BIBP3226, a specific Y1R antagonist (TOCRIS, Ellisville, MO, USA), 3) 160
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µl of 20 µg/kg prazosin, a specific α1R antagonist (Sigma-Aldrich, St. Louis, MO, USA),
4) combined 100 µg/kg BIBP3226 + 20 µg/kg prazosin, and 5) 160 µl of 5 µg/kg sodium
nitroprusside (SNP, i.v., sodium nitroprussiate dihydrate, Sigma-Aldrich, St. Louis, MO,
USA). Since the hemodynamic effects of prazosin are long lasting, BIBP3226 (Y1R
antagonist) was administered first in all experiments. When hemodynamic variables
returned to baseline (30-40 minutes), prazosin (α1R antagonist) was infused. Once
responses to prazosin peaked and stabilized (~5 minutes), combined blockade (Y1R +
α1R antagonist) was achieved by a subsequent infusion of BIBP3226 (100 µg/kg). In a
previous study (using a similar protocol), we addressed the effects of randomized versus
fixed delivery of BIBP3226 and prazosin and reported no effect of randomization
(Jackson et al., 2005a).

2.2.4.

Insulin immunoassay
Insulin levels were determined from plasma samples using an ELISA and by

following manufacturer’s instruction (ALPCO Immunoassays, Salem, NH, USA). All
samples and standards (10 µl) were distributed in duplicate in the provided 96-well
immunoplate. Seventy-five microliters of horseradish peroxidase (HRP)-labeled
monoclonal anti-insulin antibody was added to each well and incubated at room
temperature for 2 hours. The immunoplate was then washed 6 times with assay wash
buffer. Following washing, 100 µl of tetramethylbenzidine (TMB) peroxidase substrate
solution was added to each well and incubated for 15 minutes at room temperature. The
reaction was then terminated with 100 µl of stop solution, and the optical absorbance of
each well was read at 450 nm (Bio-Rad iMark Microplate Reader, Bio-Rad, Hercules,
CA, USA).
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2.2.5.

NPY immunoassay and Western blotting
Analyses were carried out on two different skeletal muscle groups known to

contain differing expression of slow-twitch oxidative (SO), fast-twitch glycolytic (FG),
and fast-twitch oxidative-glycolytic (FOG) fiber types. The use of skeletal muscle groups
expressing differing ratios of fiber types was based on early work by others showing that
blood flow to such muscles is distributed differently at rest (Terjung & Engbretson, 1988)
and during exercise (Armstrong & Laughlin, 1984; Terjung & Engbretson, 1988). We
chose to analyze vastus muscle, as it comprises the bulk of muscle tissue in the hindlimb
and plays a major role in locomotion. With the animal under deep surgical anesthesia,
skeletal muscle samples were taken from red vastus (RV; expressing FOG > FG > SO
fibers) and white vastus (WV; expressing FG > FOG) (Armstrong & Phelps, 1984;
Laughlin & Armstrong, 1983) and were flash-frozen in liquid nitrogen. Animals were
euthanized after tissue harvesting by an overdose of anesthetic. The same muscle tissue
samples were used in all assays (NPY immunoassay and Western blot).
NPY concentration was determined in whole muscle tissue homogenates (from
white and red vastus; see below for preparation of homogenate and total protein
determination) and standards (50 µl duplicate samples) using a competitive immunoassay
(Bachem Bioscience, King of Prussia, PA, USA). All samples were incubated at room
temperature for 2 hours. The immunoplate was then washed 5 times with 300 µl per well
of assay buffer. Wells were incubated at room temperature with 100 µl of streptavidinHRP for 1 hour. The immunoplate was washed again 5 times with 300 µl per well of
assay buffer. Following washing, 100 µl of a TMB peroxidase substrate solution was
added to all wells. After a 40 minute incubation at room temperature the reaction was
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terminated by the addition of 100 µl 2 N HCl. Finally, the optical absorbance of each
well was read at 450 nm (Bio-Rad Ultramark Microplate Imaging System, Bio-Rad,
Hercules, CA, USA). Absorbance measures were converted to NPY concentration by
comparison with the 10-point standard curve. Results are given as a ratio of pg NPY (per
µg tissue), relative to protein concentration, as computed from amount of total protein
loaded per well. The assay has a minimum detectable concentration of 0.04–0.06 ng per
ml or 2–3 pg per well (manufacturer's data).
White and red vastus skeletal muscle tissue was removed from the hindlimb and
flash frozen in liquid nitrogen. Approximately 100 mg of tissue was cut from the whole
muscle and homogenized in 2 mL of radioimmunoprecipitation assay lysis buffer (50
mM Tris-HCl pH 7.4, 150 mM NaCl, 1% IGEPAL, 1% Sodium deoxycholate, 0.1%
SDS, 100 mM EDTA) containing protease inhibitor cocktail (104 mM AEBSF, 80 mM
aprotinin, 2.1 mM leupeptin, 3.6 mM betastatin, 1.5 mM pepstatin A, 1.4 mM ME-64,
Sigma-Aldrich, St. Louis, MO, USA). Samples were then centrifuged at 4°C for 25
minutes at 14000 rpm and supernatant was collected and then stored at -80°C until ready
for use. Protein concentration was determined using the Bradford protein assay
(Bradford, 1976). Fifty micrograms of protein from each sample was loaded on a 4% to
12% gradient gel and separated by SDS-PAGE. After electrophoresis, proteins were
transferred at a constant voltage to polyvinylidene fluoride membranes. Membranes were
blocked in 5% milk in tris-buffered saline + Tween20 (0.5%) (TTBS) at 4°C for 5 hours.
Membranes were washed in TTBS and incubated overnight at 4°C in one of two primary
antibodies in 5% milk in TTBS, specific to rat, human or mouse: 1) Y1R (rabbit
polyclonal to NPY1R, Cat no. ab73897, Abcam, Cambridge, MA, USA), and 2) α1R
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(rabbit polyclonal to alpha 1 adrenergic receptor, Cat no. ab3462, Abcam, Cambridge,
MA, USA). After incubation, membranes were washed in TTBS then incubated in
secondary antibody conjugated to HRP (goat anti-rabbit IgG, Cat no. A0545, Sigma
Aldrich, St Louis, MO, USA) in 5% milk in TTBS for 1 hour at room temperature.
Membranes were washed and bands were detected using Immun-Star WesternC©
chemiluminescent kit (Bio-Rad, Hercules, CA, USA) and imaged with a ChemiDoc XRS
System (Bio-Rad, Hercules, CA, USA). Membranes were immediately washed, stripped,
and blocked in 5% bovine serum albumin for 1 hour at room temperature. Membranes
were washed and incubated in primary antibody specific to β-actin (loading control, antibeta actin, rabbit polyclonal, Cat no. ab16039, Abcam, Cambridge, MA, USA) for 1 hour
at room temperature. Membranes were then washed, incubated in secondary antibody and
imaged (as above). Densitometric band analysis was performed with Quantity One 1-D
Analysis Software (Bio-Rad, Hercules, CA, USA). Quantified protein expression values
were normalized to β-actin.

2.2.6.

Data acquisition and statistical analyses
All data were collected at 1 kHz with the use of the PowerLab data acquisition

system (AD Instruments, Colorado Springs, CO, USA) coupled to a computer. Heart rate
(HR) and mean arterial pressure (MAP) were calculated from arterial blood pressure
recordings. VC was calculated as a ratio of Qfem/MAP. For all conditions, Qfem, VC, MAP
and HR were calculated as a 5 minute stable average during baseline (Baseline) and as a
1 minute average at the peak of drug response (Drug).
Statistical analyses were performed using Prism (version 4, GraphPad Software
Inc, La Jolla, CA, USA) and differences were accepted as statistically significant when p
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< 0.05. Effect of treatment on MAP and HR within each group was analyzed using a
paired t-test, and between groups at baseline and drug using an unpaired t-test with a
Bonferroni correction (2 comparisons; p < 0.025). Effects of each drug perturbation on
Qfem and VC between CTRL and PD were analyzed using unpaired t-tests. The potential
synergy between Y1R and α1R activation was assessed by comparing the sum of the
drug responses from the BIBP3226 and prazosin conditions against those of the
BIBP3226 + prazosin condition using a paired t-test. Unpaired t-tests were used to
compare cellular data (from Western blot and immunoassay) between groups. Pearson’s
Correlation was used to assess correlation between body mass and Qfem or VC. Data are
presented as mean values ± standard error (SE).

2.3.

Results

Body mass, blood glucose, insulin, lactate, mean end tidal CO2 and respiratory
rate were significantly greater in PD versus CTRL (p < 0.001, Table 2.1); however,
expired O2 and blood pH were similar between groups (Table 2.1). At baseline, both
groups displayed similar MAP (85-95 mmHg); however, HR was greater in PD versus
CTRL (p < 0.025, Table 2.2).
Baseline Qfem and VC were similar between groups and similar before each drug
perturbation (Table 2.3). This observation was independent of body mass, as there was no
correlation between body mass and Qfem or VC (r = 0.11, p = 0.65). Vehicle infusion of
saline had no effect on MAP, HR, Qfem or VC in either group.
The magnitude of vascular responses to bolus infusions of ACh and SNP were
similar between groups, indicating that endothelial and smooth muscle cell functionality
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were preserved in PD (Table 2.4). Representative tracings of mean hindlimb vascular
conductance to pharmacologic interventions are shown for a CTRL and PD rat in Figure
2.1.
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Table 2.1: Physical and physiological characteristics of CTRL and PD rats.
CTRL

PD

Body mass (g)

196 ± 4

253 ± 5*

Blood glucose
(mmol/L)

9.3 ± 0.6

14.1 ± 0.9*

Insulin (nmol/L)

0.1 ± 0.03

5.6 ± 0.7*

Blood lactate
(mmol/L)

1 ± 0.1

2 ± 0.1*

Expired CO2
(mmHg)

35 ± 0.5

39 ± 0.5*

Expired O2 (%)

17 ± 0.1

17 ± 0.1

Respiratory rate
(breaths/min)

68 ± 2

82 ± 2*

Blood pH
7.4 ± 0.01
7.4 ± 0.01
Values are mean ± SE. CTRL, control, n=7-8; PD, pre-diabetic, n=7-9. *p < 0.001 vs.
CTRL.
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Table 2.2: Blood pressure and heart rate responses associated with each condition.
BIBP3226

Prazosin

BIBP3226+Prazosin

CTRL

PD

CTRL

PD

CTRL

PD

Mean arterial
pressure
(mmHg)

Baseline

95 ± 2

102 ± 6

88 ± 4

102 ± 5

88 ± 4

102 ± 5

Drug

89 ± 4

94 ± 8

72 ±5*

76 ± 6*

71 ± 3*

71 ± 6*

Heart rate
(beats/min)

Baseline

375 ± 7

414 ± 7†

371 ± 6

409 ± 8†

371 ± 6

409 ± 8†

Drug

379 ± 6

430 ± 11*†

368 ± 7

413 ± 10†

368 ± 8

406 ± 7†

Values are mean ± SE. CTRL, control, n=8; PD, pre-diabetic, n=9. *p < 0.05 vs.
Baseline. †p < 0.025 vs. CTRL.
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Table 2.3: Baseline values of hindlimb blood flow and vascular conductance before
pharmacological treatments.
BIBP3226
CTRL

Prazosin

BIBP3226+Prazosin

PD

CTRL

PD

CTRL

PD

Hindlimb blood flow
(µl/min)

385 ± 69

364 ± 42

364 ± 61

358 ± 34

364 ± 61

358 ± 34

Vascular conductance
(µl/min/mmHg)

4.0 ± 0.6

3.7 ± 0.5

4.1 ± 0.6

3.6 ± 0.4

4.1 ± 0.6

3.6 ± 0.4

Values are mean ± SE. CTRL, control, n=8; PD, pre-diabetic, n=9.
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Table 2.4: Hindlimb blood flow and vascular conductance at baseline and following
acetylcholine and sodium nitroprusside interventions.
Acetylcholine

Sodium Nitroprusside

CTRL

PD

CTRL

PD

Hindlimb blood flow

Baseline

380 ± 50

395 ± 30

385 ± 66

377 ± 47

(µl/min)

Drug

708 ± 66*

760 ± 93*

503 ± 72*

582 ± 53*

Vascular conductance
(µl/min/mmHg)

Baseline

4.2 ± 0.6

3.7 ± 0.5

4.2 ± 0.7

3.6 ± 0.6

Drug

10 ± 1*

10 ± 1*

12 ± 2*

11 ± 2*

Values are mean ± SE. CTRL, control, n=6-8; PD, pre-diabetic, n=6-8. *p < 0.05 vs.
Baseline.
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Figure 2.1: Representative hindlimb vascular conductance.
Representative mean vascular conductance (0.1 second averaging of 1 kHz beat-by-beat
tracing) over 50 seconds for BIBP3226, prazosin and BIBP3226 + prazosin treatments in
CTRL (top) and PD (bottom).
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2.3.1.

Functional effects of local Y1R and α1R blockade

2.3.1.1.

Effect of local Y1R blockade (BIBP3226)

Following Y1R antagonism, MAP was unchanged for both groups, however HR
increased from baseline in PD (p < 0.05, Table 2.2). Qfem and VC increased from
baseline in CTRL (ΔQfem = 70 ± 17 µl/min; ΔVC = 1.0 ± 0.2 µl/min/mmHg-1) and PD
(ΔQfem = 190 ± 45 µl/min; ΔVC = 2.8 ± 0.8 µl/min/mmHg) (p < 0.05), however the
increase in Qfem and VC following Y1R blockade was greater in PD compared to CTRL
(p < 0.05, Figure 2.2). Percent change in VC was greater in PD (75 ± 13%) versus CTRL
(31 ± 12%) (p < 0.05, Figure 2.3).

2.3.1.2.

Effect of local α1R blockade (prazosin)

Following α1R antagonism, MAP decreased 15 ± 2 and 26 ± 5 mmHg, for CTRL
and PD respectively (p < 0.05, Table 2.2) and HR was unchanged from baseline (Table
2.2). Qfem and VC increased from baseline in CTRL (ΔQfem = 39 ± 13 µl/min; ΔVC = 1.5
± 0.3 µl/min/mmHg) and PD (ΔQfem = 149 ± 37 µl/min; ΔVC = 3.2 ± 0.4 µl/min/mmHg),
where the increase in Qfem and VC was greater in PD compared to CTRL (p < 0.05,
Figure 2.2). Percent change in VC was greater in PD (94 ± 11%) versus CTRL (41 ± 9%)
(p < 0.05, Figure 2.3).
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Figure 2.2. Sympathetic receptor blockade elicits greater vascular responses in PD.
Panel a: Change in hindlimb blood flow (Qfem) and Panel b: vascular conductance (VC)
from baseline following Y1R and α1R blockade. With Y1R blockade, the increase in
Qfem and VC was greater in PD (n=9) versus CTRL (n=8) (p < 0.05). α1R blockade
elicited an increase in Qfem, as well as an increase in VC that was greater in PD
compared to CTRL (p < 0.05). * Indicates different from CTRL (p < 0.05).
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Figure 2.3: Percent change in hindlimb vascular conductance following Y1R and
α1R blockade.
The percent increase in VC following BIBP3226, prazosin and BIBP3226 + prazosin
treatments was greater in PD (n=9) compared to CTRL (n=8). *Indicates different from
CTRL (p < 0.05).
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2.3.1.3.

Effect of simultaneous Y1R and α1R blockade (BIBP3226 +
prazosin)

Following combined Y1R and α1R antagonism, MAP decreased 17 ± 3 and 31 ±
6 mmHg, for CTRL and PD respectively (p < 0.05, Table 2.2), whereas HR remained
unchanged. Qfem and VC increased from baseline in CTRL (ΔQfem = 191 ± 39 µl/min;
ΔVC = 3.8 ± 0.7 µl/min/mmHg) and PD (ΔQfem = 279 ± 44 µl/min; ΔVC = 5.8 ± 0.6
µl/min/mmHg) (p < 0.05), however the increase in Qfem and VC following combined Y1R
and α1R blockade was greater in PD compared to CTRL (p < 0.05, Figure 2.2). Percent
change in VC was greater in PD (170 ± 20%) versus CTRL (109 ± 24%) (p < 0.05,
Figure 2.3).
To determine the potential synergistic interaction between endogenous Y1R and
α1R activation, the sum of the VC responses from the BIBP3226 and prazosin conditions
was compared to the VC responses elicited by combined Y1R and α1R blockade within
each group. Compared to the sum of the independent effects of BIBP3226 and prazosin
infusion, combined blockade resulted in a similar increase in VC within groups (Figure
2.4).
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Figure 2.4. Y1R and α1R synergism is not observed in CTRL and PD.
Comparison of the change in hindlimb vascular conductance between CTRL (n=8) and
PD (n=9) for the sum of responses from BIBP3226 and prazosin conditions and the
BIBP3226 + prazosin condition. * Indicates different from CTRL (p < 0.05).
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2.3.2.

Tissue NPY concentration and Y1R and α1R expression

2.3.2.1.

Tissue NPY concentration

NPY concentration was 155 ± 32% and 68 ± 32% greater in white and red vastus
respectively in PD compared to CTRL (p < 0.05, Figure 2.5).

2.3.2.2.

Tissue Y1R and α1R

Compared to CTRL, Y1R protein expression was 43 ± 15% and 30 ± 9% greater
in PD white and red vastus muscle respectively (p < 0.05, Figure 2.6). α1R expression
was 94 ± 43% greater in PD compared to CTRL in red vastus muscle (p < 0.05), however
expression in white vastus muscle was similar between groups (Figure 2.7).
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Figure 2.5. Skeletal muscle NPY concentration is elevated in PD.
NPY concentration normalized to total protein for whole muscle homogenate of white
vastus (WV) and red vastus (RV). PD (n=6 per muscle group) tissue had greater NPY
concentration compared to CTRL (n=6 per muscle group). * Indicates different from
CTRL (p < 0.05).
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Figure 2.6. Y1R expression is augmented in PD.
Western blot analysis of Y1R expression (~43 kDa) in hindlimb muscle homogenate of
CTRL (n=6 per muscle group) and PD (n=6 per muscle group). PD had greater overall
expression of Y1R in both white and red vastus muscles. * Indicates different from
CTRL (p < 0.05).
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Figure 2.7. α1R expression is augmented in PD.
Western blot analysis of α1R expression (~42 kDa) in hindlimb muscle homogenate of
CTRL (n=6 per muscle group) and PD (n=6 per muscle group). PD had greater α1R
expression in red vastus muscle, compared to CTRL. * Indicates different from CTRL (p
< 0.05).
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2.4.

Discussion

As hypothesized, we observed heightened sympathetic influences on baseline
vascular control in pre-diabetes, as blockade of sympathetic receptors elicited greater
Qfem and VC responses in PD compared to CTRL. This is the first study to report that
pre-diabetes promotes an overall increase in Y1R and α1R vascular control under
baseline conditions. Accordingly, increases in skeletal muscle NPY concentration and
Y1R expression were observed in PD. However, in contrast to our hypothesis, we did not
unmask Y1R and α1R synergistic effects on VC with combined receptor blockade.
In the current study we demonstrated that modifications in sympathetic vascular
control occur before the manifestation of endothelial and/or vascular smooth muscle
dysfunction generally observed in overt type 2 diabetes. Our current data are supported
by past studies (using the same model of pre-diabetes) showing no differences in
responses to ACh or SNP in PD versus CTRL (Ellis et al., 2010; Lesniewski et al., 2008).
These data indicate that endothelium dependent and independent responses to such
pharmacological stimuli (ACh and SNP) are intact in PD, supporting the hypothesis that
vascular dysregulation in early pre-diabetes is mainly due to modifications in sympathetic
control.
Past work from our group suggests that sympathetic vascular control involves
interactions between Y1R and α1R (Jackson et al., 2005a). Until presently, there was a
lack of research investigating the role of NPY in pre-diabetic vascular dysfunction. In
fact, past investigations addressing augmented sympathetic vascular control in prediabetes have relied predominantly on the functional responses to infusion/application of
α-adrenergic agonists in vivo, or responses of isolated vascular preparations treated with
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these agents (Frisbee, 2004; Lesniewski et al., 2008). Although essential for determining
the existence of receptors and their independent function(s) within physiological systems,
the infusion of agonists does not address autogenous ligand–receptor interactions. In the
current investigation highly selective Y1R and α1R antagonists (BIBP3226 and prazosin
respectively) were delivered alone and in combination to address endogenous
independent and synergistic Y1R/α1R control under baseline conditions. Although
responses to Y1R, α1R, and combined blockade were markedly augmented in PD, we did
not unmask endogenous Y1R and α1R synergism in either CTRL or PD (Figure 3.3).
This was surprising, as we have previously reported endogenous synergy between Y1R
and α1R in adult male Sprague Dawley rats (Jackson et al., 2005a). Thus, it seems that
such receptor interactions are not present in the young ZDF rat or they were not robust
enough to resolve in the current study.
Despite similar baseline Qfem and VC among groups, we observed that both Y1R
and α1R sympathetic antagonist treatments resulted in greater vascular responses in PD.
Under conditions of heightened sympathetic influence, it seems unexpected that
similarities in baseline Qfem and VC would exist. However, our observations are
supported by other work where isolated vessels from pre-diabetic rats (with similar
baseline tone) demonstrated greater responses to sympathetic agonists compared to
controls (Lesniewski et al., 2008). Thus, in the current study, it appears that
compensatory dilatory mechanisms served to maintain normal blood flow under baseline
conditions in PD. The presence of high blood lactate (a potent vasodilator, (Chen, Wolin,
& Messina, 1996)) in PD likely contributed to buffering the effects of augmented
sympathetic vascular modulation. In support of our data, others have shown that insulin
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resistance (Lovejoy, Newby, Gebhart, & DiGirolamo, 1992) and type 2 diabetes
(Crawford et al., 2010) are associated with heightened lactate levels.
Our observations of augmented baseline Y1R and α1R activation in PD are
complemented by our findings that PD had greater NPY concentration and Y1R and α1R
expression in hindlimb skeletal muscle. Neuropeptide Y is produced in sympathetic
neuronal cell soma and packaged into secretory large dense-cored vesicles and undergoes
axonal transport (the rate of which is SNA level dependent) to the axon terminal where it
is released and eventually degraded by enzymes in the synaptic cleft (Lundberg, 1996).
This is in contrast to NE, which is produced in sympathetic nerve terminal, released, and
eventually taken back up into the nerve terminal (Eisenhofer, Goldstein, & Kopin, 1989).
Based on the unique origin and fate of NPY, it can be reasonably inferred that increased
skeletal muscle NPY concentration measured in PD was a result of one or a combination
of the following: i) augmented sympathetic neuronal density; ii) increased production and
axonal transport of NPY; and/or iii) increased NPY release into skeletal muscle
interstitium. This line of reasoning falls in line with work by others who reported
sympathetic nerve hyperactivity in insulin resistant and type 2 diabetic subjects, as well
as heightened plasma NPY levels in type 2 diabetic patients (Huggett et al., 2003; Matyal
et al., 2011). Beyond this, in vivo studies investigating NPY levels and Y1R/α1R
expression in pre-diabetes are limited; however, increased Y1R mRNA expression has
been reported in cardiac tissue of diabetic rats (Chottova Dvorakova et al., 2008) and it
was shown that rat vascular smooth muscle cells treated with high levels of insulin
resulted in upregulation of α1R (Hu, Shi, & Hoffman, 1996).
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2.4.1.

Limitations
We used hindlimb muscle homogenate in order to quantify the receptors located

along downstream resistance arterioles, as these vessels are responsible for modulating
flow at the level of the femoral artery. Previous work indicates that peripheral Y1Rs are
predominantly associated with vasculature (Franco-Cereceda & Liska, 1998). In contrast,
α1Rs have been identified on skeletal muscle fibers in rats; however, the density of those
located in muscle fibers is negligible compared to α1R expression on resistance arterioles
(Martin, Tolley, & Saffitz, 1990). Based on past reports and the internal consistency
between our functional and cellular data, we are confident that our reported differences in
ligand concentration and receptor expression reasonably reflect what is occurring at the
level of the vasculature.
We measured skeletal muscle tissue NPY concentration instead of plasma NPY
levels for several reasons. Indeed, repeated blood sampling poses the risk of evoking
hypotension and increases in sympathetic nerve activity. As well, plasma NPY levels
represent a mixed sample originating from several sources throughout the body. In
contrast, the skeletal muscle samples used in this study were promptly harvested from
anesthetized animals (with minimal hemodynamic stress) under the same conditions that
functional data were acquired. Thus, we feel that our reported NPY levels are an accurate
representation of the local skeletal muscle environment under baseline conditions.
Due to limitations in detection, NE levels were not measured in the current study.
However, this investigation and previous from our group (Jackson et al., 2010; Jackson et
al., 2005a) used a sensitive enzyme immunoassay optimized to detect NPY in skeletal
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muscle homogenates. NPY is co-released and co-stored with NE (Zofia. ZukowskaGrojec & Wahlestedt, 1993) and plasma NPY release correlates with NE release (Z.
Zukowska-Grojec, Konarska, & McCarty, 1988), especially under conditions of elevated
sympathetic nerve activity; thus, it is reasonable to postulate that our measures of
increased skeletal muscle NPY concentration in PD reflect a concomitant increase in
skeletal muscle NE.

2.5.

Conclusions

In conclusion, we provide the first report that Y1R and α1R vascular regulation is
augmented in the hindlimb of pre-diabetic ZDF rats. Our findings are supported by
increased skeletal muscle NPY concentration and Y1R/α1R expression in PD versus
CTRL. Future studies are required to ascertain the long-term cardiovascular
consequences of our findings and their functional significance in contracting skeletal
muscle.
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3.1. Introduction
Pre-diabetes affects approximately 25% of North Americans, and its prevalence
continues to rise with increased cases of obesity and sedentary lifestyle (Canadian
Diabetes Association, 2011, Disease Control and Prevention, 2011). Inherently, prediabetes is associated with impairments in cardiovascular health that manifest prior to the
onset of overt type 2 diabetes (Faeh, William, Yerly, Paccaud, & Bovet, 2007; Haffner,
Stern, Hazuda, Mitchell, & Patterson, 1990; Shin, Lee, & Lee, 2011). Characterized by
hyperinsulinemia, insulin resistance, elevated blood glucose and frequently accompanied
by obesity, the pathological metabolic characteristics of pre-diabetes play a role in the
initiation of cardiovascular complications centrally and peripherally (DeFronzo & AbdulGhani, 2011; Gupta et al., 2012; Schaefer et al., 2010); however, our knowledge
regarding the effects of pre-diabetes on skeletal muscle arteriolar function is limited.
Skeletal muscle makes up approximately 40% of body mass and contains the
greatest proportion of arterioles than any other organ (Janssen et al., 2000). Comprising
approximately 20% of the body’s total baseline systemic vascular resistance, skeletal
muscle arterioles play a key role in blood pressure regulation at rest and blood flow
redistribution during exercise. A hallmark of musculoskeletal health is ability to rapidly
match skeletal muscle blood supply to metabolic demand at rest and during physical
activity and research in the past decade provides evidence of arteriolar dysregulation in
pre-diabetes (Gorczynski et al., 1978, Laughlin and Armstrong, 1982, Fuglevand and
Segal, 1997, Lesniewski et al., 2008, Ellis et al., 2010). In 2008, Lesniewski et al.
reported increases in vasoconstrictor responsiveness to norepinephrine and endothelin-1
in 1st order arterioles isolated from the gastrocnemius of normotensive pre-diabetic
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Zucker Diabetic Fatty (ZDF) rats (Lesniewski et al., 2008). In congruence, we have
shown that, despite having normal resting blood flow, sympathetic influences on baseline
vascular control are augmented in normotensive pre-diabetic ZDF rats in vivo (Novielli,
Al-Khazraji, Medeiros, Goldman & Jackson, 2012). Taken together, it is reasonable to
conclude that skeletal muscle arteriolar dysregulation in early pre-diabetes has little to no
effect on systemic blood pressure or bulk blood flow to skeletal muscle under resting
conditions. However, the conditions described above may render skeletal muscle
microcirculation opposable to arteriolar dilation under exercise conditions, leading to
microvascular perfusion deficits.
Studies directly investigating the impact of pre-diabetes on skeletal muscle
microvascular control during exercise are limited. Certainly, human and animal studies
have illustrated impaired skeletal muscle perfusion and O2 delivery/uptake, and
compromised blood flow regulation at rest and during exercise/muscle contraction in
overt type 2 diabetes, the metabolic syndrome, and obesity (Padilla et al., 2006a, Padilla
et al., 2006b, Musa, Torrens & Clough, 2014, Blain, Limberg, Mortensen & Schrage,
2012, Vinet et al., 2011, Karpoff et al., 2009, Frisbee, 2003, Frisbee, 2004, MacAnaney,
Reilly, O’Shea, Egana & Green, 2011, Kingwell, Formosa, Muhlmann, Bradley &
McConell, 2003). However, differences in the experimental models and methodological
limitations generally constrain the current understanding of vascular control in metabolic
diseases to bulk blood flow measures. Although such studies have merit, measures of
bulk blood flow provide no information on the site or nature of arteriolar dysregulation.
Furthermore, models of overt type 2 diabetes, metabolic syndrome, and obesity are
accompanied by chronic states of cardiovascular compromise and overt vascular disease;
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where early pre-diabetes represents the primary stage of diabetic disease progression,
where vascular complications may not be as clear-cut.
Direct observations of arteriolar networks using intravital video microscopy
(IVVM) illustrate that healthy microvascular responses to contraction are non-uniform,
with greater (relative) arteriolar dilation occurring in distal versus proximal regions
(Dodd & Johnson, 1991; Marshall & Tandon, 1984; VanTeeffelen & Segal, 2006). As
well, it has been shown that arterioles respond differently to vasoactive substances
associated with muscle contraction [(e.g. potassium (M. L. Armstrong, Dua, & Murrant,
2007), adenosine (Murrant & Sarelius, 2002), acetylcholine (VanTeeffelen & Segal,
2006), lactate (Chen, Wolin, & Messina, 1996), nitric oxide (Silveira, Pereira-Da-Silva,
Juel, & Hellsten, 2003)] depending on where they reside in the network. Distal arterioles
closest to the capillaries are the first to dilate, as the sensitivity of these vessels to
metabolic vasoactive substances has been shown to be greater than proximal arterioles
(Davis, Hill, & Kuo, 2008). Furthermore, distal arterioles are able to dilate and overcome
sympathetic activation more readily than proximal arterioles within the muscle (Anderson
& Faber, 1991). Finally, studies demonstrate that sympathetic receptors located on
arterioles (responsible for vasoconstriction and maintaining arteriolar tone) are
differentially distributed at different branch orders of arteriolar networks, indicating
distinct spatial sympathetic arteriolar control (Anderson & Faber, 1991; Moore, Jackson,
& Segal, 2010). Since these studies illustrate heterogeneous arteriolar regulation in
skeletal muscle under healthy conditions, then it would be ideal to investigate arteriolar
function at different levels of continuously branching arteriolar networks in pre-diabetes.
Interestingly, deficits in post-exercise capillary perfusion have been demonstrated in
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overt type 2 diabetic subjects, where blood flow in the supplying conduit artery was not
compromised (Womack et al., 2009). These findings suggest that deficiencies in
arteriolar regulation may be apparent in the distal microcirculation before impairments of
exercise-evoked blood flow can be detected in large vessels (Kingwell et al., 2003;
MacAnaney et al., 2011). However, in an effort to determine the effects of early prediabetes on the onset of skeletal muscle microvascular dysregulation, an appropriate
model enabling concurrent observation of multiple arteriolar orders is needed.
The gluteus maximus (GM) preparation, developed by Bearden et al. (Bearden,
Payne, Chisty, & Segal, 2004), provides a unique model for investigating skeletal muscle
arteriolar control using IVVM. Unlike many other experimental skeletal muscle models,
the GM is common to both sexes, is found in all mammalian species, and is recruited
during locomotion (Bearden et al., 2004). Furthermore, due to its planar arrangement of
microvessels and uniform tissue thinness it is optically ideal for IVVM. These properties
enable comprehensive evaluation of complete arteriolar networks within a single focal
plane.
In an effort to understand the impact of early pre-diabetes on arteriolar network
regulation in skeletal muscle, our lab has refined and adapted the GM preparation in a
novel murine model of pre-diabetes, The Pound Mouse. Using this model we investigated
the effects of pre-diabetes on GM muscle branching arteriolar network function in
response to muscle contraction. Herein, we tested the hypothesis that arteriolar dilation
and blood flow in response to single tetanic and rhythmic (steady state) muscle
contractions would be blunted in pre-diabetes. Furthermore, we predicted that the greatest
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decrements in contraction-evoked vasodilation would occur in distal pre-capillary
arterioles versus proximal arterioles.

3.2.

Materials and methods

All animal procedures were approved by the Council on Animal Care at The
University of Western Ontario (protocol number: 2012-018). All invasive procedures
were performed under α-chloralose and urethane anesthetic, and all efforts were made to
minimize animal suffering.

3.2.1.

Animals
Experiments were performed on male C57BL/6NCrl (CTRL, 7-8 weeks old) and

Pound mice (PD, C57BL/6NCrl-Leprdb-lb/Crl, 7-8 weeks old). The Pound Mouse (Charles
River, Saint-Constant, QC, Canada) is a model of pre-diabetes, where these mice exhibit
a novel mutation Leprdb-lb in the leptin receptor gene. When fed a high fat diet (i.e. Purina
5008 chow), by 7 weeks of age these mice become obese, hyperinsulinemic, and have
elevated blood glucose, characteristic of the pre-diabetic condition in humans (Kim &
Reaven, 2008a, 2008b). As these mice are of C57BL/6 background, the male C57BL/6
mouse served as the control group in this study.
Mice were housed in animal care facilities in a temperature (24°C) and light (12
hour cycle)-controlled room and allowed to eat and drink water ad libitum. All mice were
obtained from Charles River Laboratories (Saint-Constant, QC, Canada) and housed in
animal care facilities for at least one week after arrival prior experimentation. Mice were
weighted prior to each experiment. After experimentation (in 5 PD and 4 CTRL), GM
muscles were excised and weighed (wet muscle mass), then dried in a laboratory oven at
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70°C for 3 hours and re-weighed (dry muscle mass). Upon completion of experimental
procedures each day, the anesthetized mouse was euthanized with an overdose of αchloralose and urethane cocktail mix (intraperitoneal injection), and cervical dislocation.

3.2.2.

Measurement of blood insulin and glucose levels
Blood insulin values were not determined in this study, as the amount of blood

sample necessary to perform the appropriate assay exceeds the ethical amount without
sacrificing the animal as specified by Western University Council on Animal Care. Blood
insulin values were instead obtained from animal characteristic data reported by Charles
River. In order to determine fasting blood glucose, mice were fasted for eight hours and
blood glucose was measured from a tail vein blood sample (~10 µl) using a Bayer
Contour

®

blood

glucose

analyzer

(Bayer,

Toronto,

ON,

Canada).

Prior

to

experimentation, mice were fed ad libitum for at least two days following fasting blood
glucose measurement.

3.2.3.

Anesthesia and muscle preparation
Using an intraperitoneal injection, the mouse was anesthetized with a cocktail of

α-chloralose (50 mg/kg) and urethane (750 mg/kg), which was supplemented as needed.
This anesthetic was ideal for these experiments as it leaves autonomic, cardiovascular
and respiratory function intact (Soma, 1983). Internal body temperature was monitored
via a rectal temperature probe and maintained at 37°C with the use of a custom made
heated surgical platform. Surgical procedures were viewed through a stereomicroscope.
The neck and backside of the mouse was shaved to remove excess fur. The mouse was
placed on its back and a mid-neck incision was made. A tracheal cannula (PE-60) was
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introduced to facilitate spontaneous respiration and (for experiments involving blood
flow measures) the right jugular vein was cannulated (PE-10 tubing) to inject fluorescent
RBCs. The neck opening was then closed using sterile stainless steel wound clips
(Autoclip 9 mm, Becton Dickinson, Franklin Lakes, NJ, USA). The mouse was then
placed in the prone position on a custom built heated stage to prepare the GM for IVVM.
Under stereomicroscopic guidance the GM muscle was cut from its origin along the spine
and along its rostral and caudal borders (Bearden et al., 2004; Jackson, Moore, & Segal,
2010). With great care taken to preserve its neurovascular supply, the muscle flap was
gently reflected away from the mouse, spread evenly onto a transparent Sylgard®
(Sylgard 184; Dow Corning, Midland, MI, USA) pedestal to approximate in situ
dimensions and pinned to secure edges. The exposed tissue was superfused continuously
(4–5 ml/min) with bicarbonate-buffered physiological salt solution (PSS, 35°C at tissue,
pH 7.4) of the following composition (mM): NaCl 137, KCl 4.7, MgSO4 1.2, CaCl2 2,
NaHCO3 18, and equilibrated with 5% CO2 ⁄ 95% N2.

3.2.4.

Fluorescent labeling of red blood cells
The red blood cell (RBC) staining protocol was adapted from Al-Khazraji et al.

2012 (Al-Khazraji, Novielli, Goldman, Medeiros, & Jackson, 2012). One day prior to
experimentation, blood was drawn from an anesthetized donor animal via cardiac
puncture into a vial containing heparin. Sample was centrifuged at 1300 g for 5 minutes,
and the plasma layer and buffy coat were discarded. Red blood cells were then washed in
Tris-buffered Ringer’s solution (room temperature, pH = 7.4), and incubated in a freshly
prepared fluorescein isothiocyanate (FITC, 0.4 mg/mL; Research Organics, Inc.,
Cleveland, OH, USA) dye solution (FITC mixed into dimethyl sulfoxide and Tris-
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buffered Ringer’s Albumin [biotechnology grade bovine albumin, 0.005 g/mL; Bioshop®
Canada Inc., Burlington, ON, Canada] solution, room temperature, pH = 7.4) for 2 hours.
Cells were washed in Tris-buffered Ringer’s Albumin solution and stored overnight at
4°C. On the day of experiment, excess dye was removed by washing cells in Trisbuffered Ringer’s Albumin solution, and hematocrit was adjusted to ~30–35% with
buffer. Prior to injection, fluorescent RBCs were imaged on a microscope and
qualitatively evaluated for fluorescence signal and cellular integrity. Prior to IVVM, cells
were injected (1% of total animal blood volume) into the animal via the jugular vein and
the line was slowly flushed with saline. It has been previously shown that FITC-labeled
fresh RBCs (one day or less) do not exhibit adherent or undeformable characteristics in
the circulation (Chin-Yee, Gray-Statchuk, Milkovich, & Ellis, 2009). In our experiments,
no plugging of capillaries with FITC-labeled RBCs was observed in the muscle
preparation.

3.2.5.

Intravital video microscopy
Upon completion of microsurgical procedures, the preparation was transferred to

the fixed stage of the intravital microscope (Olympus BX51, Olympus, Tokyo, Japan).
The preparation was equilibrated with PSS for ~30 minutes. Microvessels were observed
under Kohler illumination using a long working distance condenser (NA = 0.80) and long
working distance water immersion objectives (Olympus UMPlanFW: 10× NA = 0.30,
Olympus UMPlanFW: 20 x NA = 0.50) with illumination from a 100-Watt halogen light
source. To enhance contrast of the RBC column, a 450-nm ⁄ 20-nm band-pass filter
(450BP20; Omega Optical, Brattleboro, VT, USA) was placed in the light path. In an
effort to assess microvascular RBC velocities, fluorescent RBCs were epi-illuminated

87
using a 120-Watt Mercury Vapor Short Arc light source (EXFO, X-Cite 120PC Q,
Photonic Solutions Inc., Mississauga, ON, Canada) in line with a FITC (450–490 nm)
filter. The optical image was coupled to a front-illuminated interline CCD camera
(Qimaging Rolera E=MC2™, Qimaging , Surrey, BC, Canada) and viewed ⁄ stored to a
©

hard drive using specialized imaging software (MetaMorph® 7.6, Molecular Devices
Inc., Sunnyvale, CA, USA). Transition between bright-field and fluorescent imaging was
performed prior muscle stimulation (to obtain baseline measures) and immediately
following stimulation. Bright-field video (.tiff) images were collected (15-17 frames per
second [fps]) under Kohler bright-field illumination for off-line analysis of RBC column
diameters. Video (.tiff) images were collected (15-17 fps) under epi-illumination for offline analysis of RBC velocities, and blood flow.
Because second-order arterioles are positioned to control the distribution of blood
flow within the GM (Bearden et al., 2004) and terminal (pre-capillary) arterioles play the
greatest role in red blood cell distribution to capillaries (Pries, Ley, Claassen, &
Gaehtgens, 1989), we chose to study bifurcations at second-order arterioles (2A) to thirdorder (3A) arterioles and 3A to fourth order (pre-capillary) arterioles (4A). One arteriolar
tree (2A-4A) was studied per animal (Figure 3.1). To evaluate the viability of
experimental preparations, arterioles were tested for oxygen sensitivity by elevating
superfusate O2 from 0% to 21% (5% CO2, balance N2) for 5-8 minutes to elicit
vasoconstriction. Upon confirmation of constriction, experiments proceeded and
equilibration with 5% CO2–95% N2 was restored for the duration of experimental
procedures. Following equilibration, a video of the resting (baseline) diameter and
fluorescent RBCs was taken. Changes in arteriolar diameter (and blood flow in a subset
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of experiments; see Arteriolar and hemodynamic measurements) were evaluated in
response to brief maximal tetanic contractions at 100 Hz, as well as 30 seconds of
rhythmic muscle contractions (see Skeletal muscle contractions below). For these
experiments, each muscle preparation underwent both contraction protocols with the
order randomized across experiments.
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Figure 3.1. Gluteus maximus 2A to 4A arteriolar segments.
Representative tracings of CTRL (a) and PD (b) branching arteriolar segments within the
GM demonstrating location of second-order arterioles (2A), third-order arterioles (3A)
and fourth-order arterioles (3A). Data was collected from regions of interest at 2A-3A
and 3A-4A bifurcations, and are indicated by dotted line. Representative tracings not to
scale.
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3.2.6.

Skeletal muscle contractions
Contractions of the GM were evoked using electrical field stimulation (EFS). For

this purpose, wire electrodes (90% Pt–10% Ir; diameter, 250 µM) were positioned in the
superfusion solution on either side of the exposed muscle. Monophasic pulses (0.1 ms)
were delivered at 10 V through a stimulus isolation unit (SIU5; Grass Technologies;
Quincy, MA, USA) driven by a square wave stimulator (S48, Grass Technologies;
Quincy, MA, USA). Our experiments and previous work has shown that this voltage
elicits reproducible contractions of the GM and of arteriolar responses for the duration of
an experiment (Jackson et al., 2010). In control experiments, addition of 10 µM dtubocurarine (nicotinic cholinergic receptor antagonist) inhibited muscle contraction to
EFS, confirming that muscle contraction was a result of motor nerve activation and not
depolarization of skeletal muscle cells (Jackson et al., 2010).

3.2.6.1.

Tetanic contraction and rapid onset vasodilation

A brief maximal tetanic contraction at 100 Hz was used to evoke ROV in each
experimental group. Arteriolar dilations were evoked across stimulus train durations of
200, 400, and 800 ms with the order randomized within experiments. Arterioles
consistently returned to the initial resting baseline with 2–3 minutes of recovery between
contractions. As tissue displacement occurred during tetanic contraction, diameter was
measured preceding each stimulus (resting baseline) and immediately following
contraction with a delay of ~2-3 seconds that reflected the time the muscle is contracted
and field of view out of focus, and the time required to refocus the field of view. Blood
flow was calculated from the frames captured under fluorescent excitation prior each
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stimulus and immediately following contraction. Diameter of a 2A was tracked per
second throughout the video prior and after stimulation to demonstrate a typical arteriolar
response to tetanic muscle contraction (Figure 3.2).

3.2.6.2.

Rhythmic contraction and steady-state vasodilation

As the nature of vasodilatation can vary with the pattern of muscle fiber activation
(Murrant, 2005; VanTeeffelen & Segal, 2000), vasomotor responses to 30 seconds of
rhythmic contractions at 2 and 8 Hz (in randomized order) were also evaluated in each
experimental group. Stimulation at these frequencies evokes unfused twitch contractions
(Bearden et al., 2004). Following each 30 second period of rhythmic twitch contractions,
resting baseline was re-established consistently within 5 minutes. Arteriolar diameter was
determined preceding contractile activity, throughout the contraction period, and
following contractions throughout recovery to demonstrate the typical arteriolar response
to rhythmic contraction (Figure 3.3). Blood flow was calculated from the frames captured
under fluorescent excitation prior each stimulus and immediately following 30 seconds of
rhythmic contraction.
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Figure 3.2. Second order arteriolar response to 800 ms tetanic contraction.
Representative 2A diameter tracing of ROV in response to 800 ms single tetanic
contraction in CTRL and PD. Dotted line indicates where diameter cannot be resolved
due to displacement of the tissue at contraction and refocusing of the field of view.
CTRL, control; PD, pre-diabetic.
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Figure 3.3. Second order arteriolar response to 8 Hz rhythmic contraction.
Representative 2A diameter tracing of steady-state vasodilation in response to 30 seconds
of 8 Hz contraction in CTRL and PD. CTRL, control; PD, pre-diabetic.
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3.2.7.

Arteriolar and hemodynamic measurements
Diameters of 2A, 3A and 4A arterioles were measured manually off-line using

ImageJ software (1.43 u; National Institute of Health, Bethesda, MD, USA). Fluorescent
frames of 2A and 3A videos were analyzed to determine centerline RBC velocity (VRBC),
using the RBC “streak-length method” described in Al-Khazraji et al. 2012 (Al-Khazraji
et al., 2012). Red blood cell velocity and calculated blood flow were not determined in
4A, as making consistent measurements of ‘centerline streaks’ in 4A (using proper
measurement criteria) without moving the field of view and interrupting RCB imaging at
2A and 3A was not possible. Based on exposure times of 10-15 ms for frame rates of 1517 fps, fluorescent RBCs formed streaks in each frame. Single RBC velocities were
calculated using the equation: VRBC = (RCB streak length – RBC length)/exposure time.
Mean velocity (Vm) was then calculated using the equation: Vm = VRBC/velocity ratio.
Because velocity ratio has been shown to vary with diameter (Al-Khazraji et al., 2012),
the following equation was used to calculate diameter-specific velocity ratios of the
vessel the RBC streak is obtained from: 0.0071 x D + 1.15, where D is diameter. Blood
flow was then calculated as = π(D/2)2Vm.

3.2.8.

Statistical analyses and data presentation
Data were analyzed using SigmaStat (version 4, GraphPad Software Inc, La Jolla,

CA, USA) and considered significantly different at p < 0.05. For ROV data (diameter and
blood flow), comparisons of responses between CTRL and PD were made within each
stimulus using unpaired t-tests with a Bonferroni correction (3 comparisons) to maintain
total p < 0.05 over all comparisons. Linear regression was performed to evaluate the
correlation between the duration of tetanic contraction and the magnitude of ROV for
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each animal group. Slopes of the regression lines determined for responses at 200, 400
and 800 ms represented an index of the sensitivity of ROV responses for each animal
group (Jackson et al., 2010). Slopes of these responses were compared between groups
using an unpaired t-test. The effect of rhythmic contractions on diameter and blood flow
between CTRL and PD was also determined for each stimulus frequency using unpaired
t-tests with a Bonferroni correction (2 comparisons) to maintain total p < 0.05 over all
comparisons. To determine the effect of arteriolar order and animal group on percent
change of diameter following tetanic and rhythmic muscle contraction, a two-way
analysis of variance was used, followed by Tukey’s post-hoc comparison test to
determine where differences were significant. Differences between CTRL and PD in
tabular data were analyzed using unpaired t-tests. Summary data are presented as mean
values ± standard error, unless otherwise stated.

3.3.
3.3.1.

Results
Animal characteristics between CTRL and PD

Body mass and fasting blood glucose were approximately 2- and 2.4-fold greater
in PD versus CTRL (Table 3.1, p < 0.05). Gluteus maximus dry/wet mass ratios were
similar among groups (0.2 ± 0.02 g, Table 3.1).
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Table 3.1. Body mass, fasting blood glucose and gluteus maximus dry/wet ratio for
CTRL and PD.
Body mass (g)
Fasting blood glucose (mM/L)

CTRL

PD

22 ± 0.3

41 ± 0.7*

5±1

12 ± 1*

Dry/wet muscle mass ratio
0.2 ± 0.02
0.2 ± 0.02
Values are mean ± SEM. CTRL, control, n = 5-14; PD, pre-diabetic, n = 5-10.
* Different from CTRL, p <0.05.
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3.3.2.

Baseline arteriolar diameter, hemodynamic characteristics and
arteriolar O2 responses of CTRL and PD
Baseline 2A, 3A, and 4A diameters and 2A and 3A blood flows were similar

between CTRL and PD (Table 3.2). Arteriolar constriction in response to elevating PSS
O2 to 21% was also similar between groups for all arteriolar orders (Table 3.2).

3.3.3.

Rapid onset vasodilation, blood flow and spatial arteriolar
reactivity following single tetanic contractions
In PD, ROV (arteriolar diameter) responses to 200, 400, and 800 ms stimulations

were attenuated by 45 ± 8%, 53 ± 8%, and 48 ± 7% respectively in 2A and 36 ± 11%, 49
± 7%, and 53 ± 7% respectively in 3A; however, responses in 4A were attenuated only
under 400 and 800 ms conditions by 49 ± 7% and 49 ± 6% respectively (Figure 3.4 a, b,
c, p < 0.05). Blood flow responses in PD to 200, 400, and 800 ms stimulations were
attenuated by 68 ± 8%, 77 ± 8%, and 81 ± 6% respectively in 2A. Responses in 3A were
attenuated only following 400 and 800 ms stimulations by 60 ± 11% and 67 ± 7%
respectively in PD versus CTRL (Figure 3.4 d and e, p < 0.05).
The slope of the regression line determined for mean peak vasodilatory responses
across the range of contraction durations was interpreted as an index of the ROV
sensitivity for each experimental group. There was a strong positive correlation between
increasing contraction duration on diameter change in 2A, 3A and 4A for both groups;
however, ROV sensitivity across arteriolar orders was blunted in PD (Figure 3.5, p <
0.05).
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In an effort to compare spatial ROV reactivity across arteriolar branch orders,
changes in diameter were normalized to respective baselines and presented as % diameter
change. In CTRL, relative changes in diameter following 200 and 400 ms single tetanic
contractions were greatest in 4A (Figure 3.6 a and b, p < 0.05). After 800 ms stimulation,
CTRL 3A and 4A were equally reactive, where their responses were greater than CTRL
2A (Figure 3.6 c, p < 0.05). As expected, relative changes in diameter following 200,
400, and 800ms tetanic contraction were blunted at all arteriolar orders in PD versus
CTRL (Figure 3.6, p < 0.05). However, in PD, greater ROV reactivity was only observed
in 4A versus 2A, and only after 400 and 800 ms stimulations (Figure 3.6 b and c, p <
0.05).
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Table 3.2. Gluteus maximus arteriolar baseline diameter, blood flow and responses
to elevated O2 (21%).
2A

3A

4A

CTRL

PD

CTRL

PD

CTRL

PD

Diameter (µm)

19 ± 1

20 ± 1

14 ± 1

13 ± 1

8±1

9±1

Blood flow (nl/sec)

1 ± 0.1

1 ± 0.1

0.5 ± 0.07

0.4 ± 0.04

---

---

O2 response (µm)

-5 ± 1

-5 ± 1

-3 ± 1

-4 ± 1

-2.4 ± 0.2

-2.2 ± 0.2

Values are mean ± SEM. CTRL, control, n = 6-14; PD, pre-diabetic, n = 5-10.
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Figure 3.4. Rapid onset vasodilation and blood flow responses of arterioles following
tetanic muscle contraction are blunted in PD.
Diameter changes of 2A (a), 3A (b) and 4A (c) following tetanic contraction. Rapid onset
vasodilation was blunted in PD (n=5-10) compared to CTRL (n=6-14) following 200,
400 and 800 ms contractions for 2A and 3A, and 400 and 800 ms contractions for 4A.
The magnitude of blood flow responses of 2A (d) and 3A (e) following tetanic
contractions was also attenuated in PD (n=5-7) compared to CTRL (n=6-7). * Different
vs. CTRL, p < 0.05. CTRL, control; PD, pre-diabetic.
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Figure 3.5. Sensitivity of ROV responses to increasing tetanic contraction duration.
For both CTRL and PD, duration of tetanic muscle contraction correlated with the
increase in 2A (a), 3A (b) and 4A (c) diameter. The slope of diameter change to
increasing tetanic contraction duration was less steep in PD (n = 5-10) compared to
CTRL (6-14), demonstrating a decreased sensitivity to increasing duration of tetanic
contraction. * Slope different from CTRL, p < 0.05. CTRL, control; PD, pre-diabetic.
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Figure 3.6. Percent diameter change of ROV at arteriolar orders.
Percent change in diameter following brief 200 ms (a), 400 ms (b) and 800 ms (c) tetanic
contractions. Across the range of tetanic contractions, the percent change in diameter was
attenuated in PD (n= 5-10) compared to CTRL (n=6-14) at 2A, 3A and 4A. Within
CTRL, the relative change of 4A diameter was greater compared to 2A and 3A following
200 ms and 400 ms tetanic contractions. Following 800 ms tetanic contraction, the
relative change of both 3A and 4A ROV responses were greater than 2A. In contrast,
arteriolar order did not have an effect on PD ROV responses following 200 ms tetanic
contraction. Following 400 ms and 800 ms tetanic contractions, the relative change in 4A
diameter was only greater than 2A. * Different vs. CTRL, p < 0.05; # different vs.
responses of other arterioles within CTRL, p < 0.05;  Different vs. 2A response within
PD, p < 0.05. CTRL, control; PD, pre-diabetic.
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3.3.4.

Steady-state vasodilation, blood flow and spatial arteriolar
reactivity following rhythmic contractions
In PD, the steady-state arteriolar response to 30 seconds of 2 and 8 Hz rhythmic

contractions was attenuated by 45 ± 9% and 33 ± 8% respectively in 2A, 48 ± 6% and 47
± 7% respectively in 3A, and 38 ± 8% and 53 ± 9% respectively in 4A (Figure 3.7 a, b
and c, p < 0.05).
Although steady-state blood flow responses in 2A to 2 Hz stimulation were
similar between groups, the steady-state blood flow response in 2A to 8 Hz stimulation
was attenuated by 61 ± 9% in PD. In 3A, steady-state blood flow responses were blunted
following 2 and 8 Hz stimulation by 70 ± 7% and 71 ± 8% respectively (Figure 3.7 d and
e, p < 0.05).
In an effort to compare spatial reactivity to rhythmic contractions across arteriolar
branch orders changes in diameters were normalized to respective baselines and
presented as % diameter change. In CTRL, relative changes in diameter following 2 Hz
rhythmic contractions were greatest in 3A and 4A (Figure 3.8 a, p < 0.05) and reactivity
to 8 Hz stimulation was greatest in 4A (Figure 3.8 b, p < 0.05). As expected, relative
changes in diameter following 2 and 8 Hz rhythmic contractions were blunted at all
arteriolar orders in PD versus CTRL (Figure 3.8, p < 0.05). In PD, greater reactivity was
observed in 4A versus 2A and 3A under 2 Hz stimulation (Figure 3.8 a, p < 0.05), but
there were no differences among arteriolar orders with 8 Hz stimulation (Figure 3.8 b).
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Figure 3.7. Arteriolar dilation and blood flow responses are compromised in PD
following rhythmic contraction.
Diameter change of 2A (a), 3A (b) and 4A (c) following 30 seconds of rhythmic
contraction. The magnitude of dilation was blunted in PD (n = 5-10) compared to CTRL
(n = 5-14) following 2 Hz and 8 Hz rhythmic contractions. 2A (d) and 3A (e) blood flow
changes in response to steady-state contraction were also blunted in PD (n = 5-6)
compared to CTRL (n = 5-6). * Different vs. CTRL, p < 0.05. CTRL, control; PD, prediabetic.
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Figure 3.8. Percent diameter change to rhythmic contraction at arteriolar orders.
Percent change in diameter following 30 seconds of 2 Hz (a) and 8 Hz (b) rhythmic
contractions. Following 2 and 8 Hz contractions, the percent change in diameter was
blunted at 2A, 3A and 4A in PD (n=5-10) compared to CTRL (n=5-14). Within groups,
dilatory responses to 2 Hz contraction elicited greater responses at 3A and 4A compared
to 2A for CTRL, and greater responses of 4A compared to 3A and 2A for PD. 8 Hz
contraction elicited a greater vasodilatory response at 4A compared to 2A and 3A in
CTRL. In contrast, the magnitude of PD vasodilatory responses following 8 Hz
contraction did not differ between 2A, 3A and 4A. * Different vs. CTRL p < 0.05; #
different vs. responses of other arterioles within CTRL, p < 0.05; ¥ different vs.
responses of other arterioles within PD, p < 0.05. CTRL, control; PD, pre-diabetic.
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3.4.

Discussion

Using a novel pre-diabetic murine model (i.e., The Pound Mouse) and an innovative
experimental approach, we investigated whether pre-diabetes may modify arteriolar
responses to skeletal muscle contraction in branching arteriolar networks. For the first
time, we report that pre-diabetes leads to attenuation of vasodilation and blood flow
responses in branching arterioles by up to 50% and 80% respectively following single
tetanic and rhythmic muscle contraction. Furthermore, as predicted, we observed that the
greatest decrements in contraction-evoked vasodilation in pre-diabetes occur in distal
versus proximal arterioles.

3.4.1.

Pre-diabetes modifies arteriolar responses to muscle contraction

3.4.1.1.

Rapid onset vasodilation and blood flow

A rapid increase in blood flow to active muscle fibers is a key determinant of
work/exercise tolerance. Upon the initiation of muscle contraction in humans, ROV has
been shown to occur almost instantaneously (i.e., within the first few cardiac cycles),
eliciting an immediate increase in muscle blood flow (Tschakovsky et al., 2004, Kirby,
Carlson, Markwald, Voyles & Dinneno, 2007, Corcondilas, Koroxenidis & Shepherd,
1964, Carlson et al., 2008, Tschakovsky and Sheriff, 2004, Casey and Joyner, 2012). The
robust increase in muscle blood flow during ROV serves to initiate a rest-to-exercise
transition, such that blood flow can thereafter be maintained at a steady-state level
proportional to metabolic demand.

In contrast to sustained or repeated muscle

contraction, single brief tetanic contraction elicits ROV too quickly to be a result of the
accumulation of vasoactive metabolites (Wunsch et al., 2000). Recently, however, studies

107
using the hamster cremaster muscle have confirmed that the production of both potassium
and adenosine occurs rapidly enough following initial contraction to contribute to rapid
onset vasodilation (Armstrong et al., 2007, Ross, Mihok & Murrant, 2013). Additionally,
cell-to-cell coupling via gap junction channels provides an electrical pathway for rapid
coordination of smooth muscle cell relaxation that ascends arteriolar networks (i.e., from
terminal to proximal arterioles), known as ascending conducted vasodilation. Ascending
conducted vasodilation occurs in normal healthy skeletal muscle microvessels and is
necessary for blood flow to quickly meet metabolic demand (Segal, 2005). With the use
of animal models, direct observation of the resistance vasculature in cremaster, check
pouch retractor and GM muscles have also demonstrated ROV to single brief whole
muscle and muscle fiber bundle contraction (VanTeeffelen and Segal, 2006, Jackson et
al., 2010, Mihok and Murrant, 2004, Armstrong et al., 2007).
To date, there is a dearth of human and animal studies investigating ROV
responses in pre-diabetes. In fact, the only other study to address ROV in metabolic
disease was conducted by Blain et al. in 2012, where they examined ROV responses
(presented as changes in brachial artery vascular conductance) in obese humans (Blain et
al., 2012). Our data are in congruence with Blain et al., where they reported deficits in
ROV of approximately 40% in obese versus lean adults. As well, they reported that
impairments in ROV became greater with increased workloads in obese subjects, which
coincides with our finding that the sensitivity of ROV to increasing contraction duration
was decreased in PD versus CTRL. The correspondence between data presented by Blain
et al. in obese humans and the current findings in The Pound Mouse highlights the
translational merit of our experimental preparation.
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In the current study we used a novel approach to directly measure blood flow at
2A and 3A, where we observed that attenuated ROV in PD resulted in notable decreases
in functional hyperemia. The global blunting of ROV and blood flow responses in PD
suggests that overall arteriolar network resistance is augmented in this model.
Interestingly however, despite observing contraction-duration-dependent increases in
arteriolar dilation in PD (Figure 3.4 a, b and c, and Figure 3.5), increasing contraction
duration did not result in concomitant increases in arteriolar blood flow (Figure 3.4 d and
e). These data suggest that upstream arteriolar resistance restrains overall network blood
flow in this model. Such modifications in overall network resistance/control in prediabetes may be due to alterations in mechanisms that coordinate (e.g., connexin 40,
calcium-activated potassium channels, inward rectifying potassium channels) or restrict
(e.g. heightened sympathetic nervous system activity) ascending conducted dilation
(Haug & Segal, 2005; Twynstra, Ruiz & Murrant, 2012; VanTeeffelen & Segal, 2003).
Indeed, all of the aforementioned modifications in vascular “machinery” may be
modified in metabolic diseases (Haddock et al., 2001; Novielli et al., 2012; Young, Hill,
Wiehler, Triggle, & Reid, 2008).

3.4.1.2.

Steady-state vasodilation and blood flow

In contrast to brief tetanic contraction, sustained rhythmic muscle contraction
elicits a gradual and steady-state dilatory response, where muscle blood flow increases
and is maintained based on the metabolic demands of the tissue (R. B. Armstrong &
Laughlin, 1985; Bockman, 1983; Mohrman & Regal, 1988). This sustained vasodilatory
effect is understood to occur due to accumulation of vasoactive metabolites (Clifford &
Hellsten, 2004). In the current study, rhythmic contractions elicited robust vasodilation in

109
2A, 3A and 4A in CTRL; however, responses were attenuated up to 53% in PD.
Additionally, 2A and 3A blood flow responses were blunted up to 71% in PD. Although
there is a paucity of studies investigating steady-state vasodilation in pre-diabetes, the
effects of overt type 2 diabetes on steady-state vasodilation have been relatively well
defined and are in congruence with our findings. For example, in type 2 diabetic humans,
leg blood flow and forearm capillary perfusion was reported to be attenuated up to 65%
following steady-state exercise (Kingwell et al., 2003; Menon et al., 1992; Womack et
al., 2009), effects that likely contribute to impaired exercise capacity in this cohort
(Seyoum, Estacio, Berhanu, & Schrier, 2006). Decrements in steady-state vasodilation
noted in the current study may be due to attenuated nitric oxide-mediated vasodilation
(Lesniewski et al., 2008) and/or augmented sympathetic regulation (Novielli et al., 2012),
both of which have been reported using in vitro and in vivo rodent models of prediabetes. Indeed, impairments in endothelial function (Bakker, Eringa, Sipkema, & van
Hinsbergh, 2009; McVeigh et al., 1992) can contribute to attenuated vasodilatory
responses to muscle contraction in overt type 2 diabetes (Kingwell et al., 2003).
However, the impact of pre-diabetes on endothelial function remains equivocal (likely
due to experimental and temporal differences across studies), as it has been reported that
acetylcholine-mediated vascular responses are conserved in these conditions (Ellis et al.,
2010; Lesniewski et al., 2008; Novielli et al., 2012). These data highlight the need for
future studies which aim to elucidate the mechanisms involved in arteriolar dysregulation
in early pre-diabetes.
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3.4.2.

Pre-diabetes modifies spatial reactivity of vasodilation during
contraction
As discussed above, arteriolar responses to muscle contraction are coordinated

such that dilation ascends the network from terminal to proximal arterioles. Along the
same line, the magnitude of arteriolar vasodilation differs based on the location of the
arteriole within the microvascular network where proportional increases in vasodilation
are greatest in smaller distal arterioles compared to proximal larger arterioles (Dodd &
Johnson, 1991; Marshall & Tandon, 1984; VanTeeffelen & Segal, 2006).
Building on the aforementioned notion of spatially-dependent arteriolar reactivity
during muscle contraction, in CTRL we observed that proportional changes in arteriolar
dilation increase with contraction duration and frequency, as well as increasing arteriolar
order (Figures 3.6 and 3.8). However, as hypothesized, the magnitude and spatiallydependent pattern of arteriolar vasodilation was minimized in PD, where there was little
to no delineation between responses across arteriolar orders in either contraction
paradigm. As such, the reactivity of terminal arterioles (4A) seems to be affected most in
PD, which would have the greatest impact on RBC distribution to capillaries (Pries et al.,
1989). Our data are in support of an earlier human study where contraction-evoked
increases in forearm capillary blood flow were impaired in type 2 diabetics, despite
having normal brachial artery blood flow responses (Womack et al., 2009).
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3.5.

Conclusions

In conclusion, our data illustrate network-wide arteriolar dysregulation in response to
muscle contraction in pre-diabetes, a condition that results in severe decrements in
functional hyperemia. Arteriolar dysregulation observed in PD was demonstrated as
compromised ROV and steady state vasodilation, as well as blood flow responses,
following single tetanic and sustained rhythmic contractions in branching 2A, 3A and 4A.
Furthermore, spatial reactivity of PD vasodilatory responses was disrupted compared to
CTRL, where distal arterioles were most affected. These data may suggest a spatial and
temporal progression of diabetic vascular disease, where impairments in distal
microvasculature likely occur before dysfunction can be detected in large conduit vessels.
For future studies, the current data underscore the importance of studying multiple levels
of the skeletal muscle microcirculation in an effort to elucidate the mechanisms involved
in early pre-diabetic arteriolar dysregulation during muscle contraction.
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Chapter 4 : Y1- and α1-adrenergic receptor activation attenuates
contraction-evoked vasodilation in branching skeletal muscle
arterioles of young pre-diabetic mice
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4.1. Introduction
Peripheral vascular complications associated with type 2 diabetes (Creager,
Luscher, Cosentino, & Beckman, 2003) are initiated well before manifestation of chronic
diabetic disease, but rather in the pre-diabetic state (Ellis et al., 2010; Gupta et al., 2012;
Lesniewski et al., 2008; Milman & Crandall, 2011; Reusch, Bridenstine, & Regensteiner,
2013; Schaefer et al., 2010; Tooke & Goh, 1999; Wiernsperger, 1994). Pre-diabetes is a
condition of elevated blood glucose, insulin resistance, and hyperinsulinemia that occurs
prior to pancreatic β-cell failure and overt type 2 diabetes. Notably, the severity of insulin
resistance and elevated plasma insulin has been shown to correlate with the degree of
microvascular dysfunction (Jaap, Hammersley, Shore, & Tooke, 1994; Jaap, Shore, &
Tooke, 1997). The microvasculature plays an integral role in regulating blood flow
distribution throughout tissues, especially skeletal muscle due to its dynamic range of
metabolic demand. In exercising muscle, the arterioles play an integral role in modulating
tissue blood flow and thereby directing flow to capillary units supplying active skeletal
muscle fibers (Fuglevand & Segal, 1997). Most recently, our group has demonstrated
blunted rapid onset vasodilation (ROV) and blood flow to brief tetanic contraction, as
well as blunted steady-state vasodilation and blood flow to sustained rhythmic twitch
contractions in skeletal muscle arterioles of pre-diabetic mice (currently in review).
However the mechanisms governing decrements in contraction-evoked arteriolar
responses in pre-diabetes are not well defined.
Only few studies have investigated potential contributors to skeletal muscle
microvascular dysregulation in pre-diabetes. Earlier studies using isolated arterioles from
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the hindlimb of young pre-diabetic Zucker Diabetic Fatty (ZDF) rats demonstrated that
vasoconstrictor responsiveness to norepinphrine and endothelin-1 is enhanced
(Lesniewski et al., 2008). Additionally, previous work from our group has demonstrated
heightened sympathetic neuropeptide Y1 receptor (NPY Y1R) and alpha 1 adrenergic
receptor (α1R) modulation of resting vascular tone in the hindlimb of pre-diabetic ZDF
rats, where Y1R, α1R and NPY expression were upregulated in hindlimb tissue (Novielli
et al., 2012). Collectively, these findings provide evidence of elevated sympathetic
nervous system influences on vascular control in pre-diabetes. Elevated sympathetic
vascular control in pre-diabetes may compromise arteriolar modulation of skeletal muscle
blood flow, which may play a role in the reductions of capillary red blood cell supply
rate, velocity and oxygen saturations observed in skeletal muscle of pre-diabetic ZDF rats
(Ellis et al., 2010). Until recently however, no studies have directly assayed arteriolar
function (in vivo) throughout microvascular networks in response to skeletal muscle
contraction in pre-diabetes.
Physical activity is accompanied by increases in sympathetic nerve activity
(SNA), which modifies the distribution of cardiac output to sites of highest metabolic
activity (Rowell, 1993). Heightened SNA can limit skeletal muscle arteriolar vasodilation
and concomitant increases in blood flow (Thomas & Segal, 2004). In contracting skeletal
muscle, direct observations of arterioles confirm that vasodilatory and hyperemic
responses override elevated sympathetic activation (Remensnyder, Mitchell, & Sarnoff,
1962). The ability to overcome this effect is termed ‘functional sympatholysis’, which
enables arterioles to increase blood flow to active muscle fibers (Strandell & Shepherd,
1967). With the use of microneurography and quantification of plasma catecholamines,
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studies have demonstrated that hyperinsulinemia, a result of insulin resistance in prediabetes, correlates with elevated SNA (Anderson, Balon, Hoffman, Sinkey, & Mark,
1992; Berne, Fagius, Pollare, & Hjemdahl, 1992; DeFronzo & Ferrannini, 1991; Scherrer
& Sartori, 1997). As such, heightened sympathetic activity to skeletal muscle arterioles
and decreased symptholysis may contribute to decrements in contraction-evoked
vasodilation and hyperemic responses in pre-diabetes (McDaid, Monaghan, Parker,
Hayes, & Allen, 1994).
In conditions where heightened SNA is commonly observed, such as aging and
the metabolic syndrome, impaired skeletal muscle blood flow has been attributed to
enhanced sympathetic α-adrenergic modulation of the vasculature (Casey & Joyner,
2012; Frisbee, 2004; Jackson, Moore, & Segal, 2010). However, it is well established that
sympathetic NPY activation of Y1R plays an important role in skeletal muscle
microvascular regulation (Jackson, Milne, Noble, & Shoemaker, 2005; Jackson, Noble, &
Shoemaker, 2004), where our previous work has demonstrated that heightened Y1R and
α1R modulation of vascular conductance and blood flow in pre-diabetic ZDF rats under
resting conditions (Novielli et al., 2012). Thus, it is possible that such conditions may be
responsible for blunted contraction-evoked arteriolar responses we recently observed in
skeletal muscle (gluteus maximus; GM) arteriolar networks of pre-diabetic mice.
A recent study by our group investigated the effect of pre-diabetes on arteriolar
function in contracting skeletal muscle. In pre-diabetic mice, we demonstrated that
arteriolar dilation and blood flow responses of GM microvasculature were compromised
following both tetanic and steady-state muscle contraction. Evaluating contraction-
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evoked vasodilatory responses at multiple locations in the GM arteriolar network
revealed that relative changes in arteriolar diameter (relative to baseline diameter) were
not identical throughout the network. We found that smaller distal arterioles of healthy
control mice dilated to a greater extent compared to larger proximal arterioles, a result
corresponding with previous work characterizing vasomotor responses of skeletal muscle
microvasculature (Dodd and Johnson, 1991, Marshall and Tandon, 1984, VanTeeffelen
and Segal, 2006). In contrast, spatially-dependent arteriolar reactivity to muscle
contraction was disrupted in pre-diabetic mice. Interestingly, distal arterioles have been
shown to overcome sympatholysis more readily than upstream vasculature (Dodd and
Johnson, 1991). Under conditions of heightened sympathetic vascular modulation
however, as we have previously demonstrated in pre-diabetic rats, sympatholysis may
occur to a lesser extent, and lead to impairments in distinct spatial arteriolar responses to
muscle contraction.
Therefore, the purpose of this study was to investigate if attenuated arteriolar
dilation in response to brief tetanic and sustained rhythmic muscle contraction in prediabetes is a result of heightened arteriolar sympathetic Y1R and α1R activation. We
hypothesized that Y1R and α1R blockade would restore contraction-evoked arteriolar
dilatory responses in pre-diabetic mice (PD) to levels observed in control mice (CTRL).
We also hypothesized that impaired spatially-dependent arteriolar responses would be
restored via sympathetic Y1R and α1R blockade. Additionally, we hypothesized that
arteriolar vasoconstrictor reactivity to sympathetic agonists phenylephrine (PE) and NPY
would be greater in PD compared to CTRL.
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4.2.

Materials and methods

All animal procedures were approved by the Council on Animal Care at The
University of Western Ontario (protocol number: 2008-066). All invasive procedures
were performed under α-chloralose and urethane anesthetic, and all efforts were made to
minimize animal suffering.

4.2.1.

Animal care and use
Experiments were performed on male C57BL/6NCrl (7-8 weeks old) and Pound

mice (C57BL/6NCrl-Leprdb-lb/Crl, 7-8 weeks old). The Pound mouse is a model of prediabetes, where these mice exhibit a novel mutation Leprdb-lb in the leptin receptor gene.
When fed a high fat diet (i.e. Purina 5008 chow), mice become obese by 7 weeks of age,
exhibiting hyperinsulinemia, and elevated blood glucose, characteristic of the prediabetic condition in humans (Kim & Reaven, 2008a, 2008b). As these mice are of
C57BLK6 background, the male C57BLK6 mouse served as the control group in this
study. Mice were housed in animal care facilities in a temperature (24°C) and light (12
hour cycle)-controlled room and allowed to eat and drink water ad libitum. All mice were
obtained from Charles River Laboratories (Saint-Constant, QC, Canada) and housed in
animal care facilities for at least one week after arrival prior experimentation. Mice were
weighted prior to each experiment. Upon completion of experimental procedures each
day, the anesthetized mouse was euthanized with an overdose of α-chloralose and
urethane cocktail mix (intraperitoneal injection), and cervical dislocation.
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4.2.2.

Measurement of serum insulin levels and blood glucose levels
Blood insulin values were not determined from mice used in this study, as the

amount of blood sample necessary to perform the appropriate assay exceeds the ethical
amount without sacrificing the animal as specified by the Animal Care Council. Blood
insulin values were instead obtained from animal characteristic data reported by Charles
River. Fasting blood glucose was sampled from animals no later than two days before
experimentation. Mice were fasted for eight hours and blood glucose was sampled from
the tail vein (~10µl) and determined with a Bayer Contour blood glucose analyzer
®

(Bayer, Toronto, ON, Canada).

4.2.3.

Anesthesia and skeletal muscle preparation
Using an intraperitoneal injection, the mouse was anesthetized with a cocktail of

α-chloralose (50 mg/kg) and urethane (750 mg/kg), which was supplemented throughout
the experiment as needed. This anesthetic was ideal for these experiments as it leaves
autonomic, cardiovascular and respiratory function intact (Soma, 1983). Internal body
temperature was monitored via a rectal temperature probe and maintained at 37°C with
the use of a heating platform. Surgical procedures were viewed through a
stereomicroscope. The neck and backside of the mouse was shaved to remove excess fur.
The mouse was placed on its back and a mid-neck incision was made. A tracheal cannula
(PE-60) was introduced to facilitate spontaneous breathing. The neck opening was then
closed using wound clips (Autoclip 9 mm, Becton Dickinson, Franklin Lakes, NJ, USA).
The mouse was then placed in the prone position on the heated platform to prepare the
GM for intravital microscopy. Under stereomicroscopic guidance the GM muscle was cut
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from its origin along the spine and along its rostral and caudal borders (Bearden, Payne,
Chisty, & Segal, 2004; Jackson et al., 2010). With great care taken to preserve its
neurovascular supply, the muscle flap was gently reflected away from the mouse, spread
evenly onto a transparent Sylgard (Sylgard 184; Dow Corning, Midland, MI, USA)
®

pedestal to approximate in situ dimensions and pinned to secure edges. The exposed
tissue

was

superfused

continuously

(4–5

mL⁄min)

with

bicarbonate-buffered

physiological salt solution (PSS, 35°C at tissue, pH 7.4) of the following composition
(mM): NaCl 137, KCl 4.7, MgSO4 1.2, CaCl2 2, NaHCO3 18, and equilibrated with 5%
CO2 ⁄ 95% N2.

4.2.4.

Intravital video microscopy
Upon completion of microsurgical procedures, the preparation was transferred to

the stage of the intravital microscope (Olympus BX51, Olympus, Tokyo, Japan). The
preparation was equilibrated with PSS for ~30 minutes. Microvessels were observed
under Kohler illumination using a long working distance condenser (NA = 0.80) and long
working distance water immersion objectives (Olympus UMPlanFW: 10× NA = 0.30)
with illumination from a 100-Watt halogen light source. To enhance contrast of the RBC
column, a 450-nm ⁄ 20-nm band-pass filter (450BP20; Omega Optical, Brattleboro, VT,
USA) was placed in the light path. The optical image was coupled to a front-illuminated
interline CCD camera (Qimaging Rolera E=MC2™, Qimaging , Surrey, BC, Canada) and
©

viewed ⁄ stored to a hard drive using specialized imaging software (MetaMorph® 7.6,
Molecular Devices Inc., Sunnyvale, CA, USA). Bright-field video (.tiff) images were
collected (15-17 fps) under Kohler bright-field illumination for off-line analysis of RBC
column diameters.
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Bifurcations at second-order arterioles (2A) to third-order (3A) arterioles and 3A
to fourth order arterioles (4A) were chosen for study, as these resistance microvessels are
positioned to control the distribution of blood flow within the GM and to the capillaries
(Bearden et al., 2004; Pries, Ley, Claassen, & Gaehtgens, 1989). One arteriolar tree (2A4A) was studied per animal. Following equilibration, a video of the resting (baseline)
diameter was taken. Arterioles were then tested for oxygen sensitivity by elevating
superfusate O2 from 0% to 21% (5% CO2, balance N2) for 5-8 minutes to elicit
vasoconstriction. Equilibration with 5% CO2–95% N2 was restored for the duration of
experimental procedures. Changes in arteriolar diameter were evaluated in response to
brief maximal tetanic contractions at 100 Hz as well as 30 seconds of rhythmic muscle
contractions (see Skeletal muscle contractions). For these experiments, each muscle
preparation underwent both contraction protocols with the order randomized across
experiments. At the end of each day’s procedures, maximum arteriolar diameter was
recorded by adding sodium nitroprusside (SNP, 10 µM) to the superfusate (Bearden et
al., 2004; Jackson et al., 2010; VanTeeffelen & Segal, 2006). It was determined however,
that vasodilation of PD 2A and 3A to SNP was less than that of CTRL arterioles.
Responses of PD arterioles to SNP were then tested with 100nM BIBP3226 (Y1R
antagonist) and 100nM prazosin (α1R antagonist) within the PSS. This was performed in
an effort to determine if enhanced arteriolar sympathetic receptor activation contributes
to decreased vasodilation to SNP in PD.

4.2.5.

Skeletal muscle contractions
Contractions of the GM were evoked using electrical field stimulation (EFS). For

this purpose, wire electrodes (90% Pt–10% Ir; diameter, 250 µm) were positioned in the
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superfusion solution on either side of the exposed muscle. Monophasic pulses (0.1 ms)
were delivered at 10 V through a stimulus isolation unit (SIU5; Grass Technologies;
Quincy, MA, USA) driven by a square wave stimulator (S48, Grass). Our experiments
and previous work has shown that this voltage elicited reproducible contractions of the
GM and of arteriolar responses for the duration of an experiment (Jackson et al., 2010).

4.2.5.1.

Tetanic contraction and rapid onset vasodilation

A brief maximal tetanic contraction at 100 Hz was used to evoke ROV in each
experimental group. Arteriolar dilations were evoked for stimulus train durations of 400
and 800 ms, with the order randomized across experiments. The arteriole consistently
returned to the initial resting baseline with 2–3 minutes of recovery between contractions.
As tissue displacement occurred during tetanic contraction, diameter was measured
preceding each stimulus (resting baseline) and immediately following contraction with a
delay of ~2 seconds that reflected the time the muscle is contracted and field of view out
of focus, and the time required to refocus the field of view.

4.2.5.2.

Rhythmic contraction and steady-state vasodilation

As the nature of vasodilatation can vary with the pattern of muscle fiber activation
(Murrant, 2005; VanTeeffelen & Segal, 2000), vasomotor responses to 30 seconds of
rhythmic contractions at 2 and 8Hz (in randomized order) were also evaluated in each
experimental group. Stimulation at these frequencies evoked unfused twitch contractions
(Bearden et al., 2004). Following each 30-second period of rhythmic twitch contractions,
resting baseline was re-established consistently within 5 minutes. Arteriolar diameter was
determined preceding contractile activity and following contraction period.
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4.2.6.

Muscle contraction experimental conditions
Arteriolar vasodilatory responses to tetanic and rhythmic contraction were first

evaluated under control conditions, where PSS was superfused over the GM. Upon
establishing differences in vasodilatory responses between CTRL and PD, we sought to
determine whether this difference was attributed to alterations in peripheral sympathetic
Y1R and α1R arteriolar activation. In an effort to recover PD dilatory responses to those
of CTRL, i) Y1R, ii) α1R and iii) Y1R+α1R were blocked using BIBP3226 (100nM) and
prazosin (100nM) (TOCRIS, Bristol, United Kingdom). Concentrations did not affect
resting baseline diameter. Sympathetic antagonist concentrations used were determined
based on the ability to reduce arteriolar constriction elicited by supersusion of 10-8 M
NPY and 10-5 M PE (data not shown). In a similar fashion, experiments were performed
in CTRL to blunt contraction-evoked arteriolar vasodilation to responses similar to PD.
Sympathetic i) Y1R, ii) α1R and iii) Y1R+α1R were activated using neuropeptide Y
(100pM) and PE (10nM). Agonist concentrations were determined from concentrations
eliciting low arteriolar reactivity, while blunting vasodilatory responses to skeletal
muscle contraction. Agents were added to superfusion solution to working concentrations
and allowed to equilibrate with the tissue, having little effect on resting baseline arteriolar
diameter. The order of drug perturbations per animal group was performed in random
order.

4.2.7.

Arteriolar reactivity to sympathetic receptor agonists
Vasoconstrictor responses of CTRL and PD 2A, 3A and 4A to sympathetic Y1R

and α1R agonists NPY (Y1R agonist, 10-13-10-8 M) and PE (α1R agonist, 10-9-10-5 M)
were investigated. The order of NPY and PE perturbations were performed in random
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order for each experiment, where resting diameter was allowed to recover in between
each set of drug perturbations. Baseline diameter prior to the addition of drug to PSS was
recorded. At each concentration of NPY or PE, arteriolar diameter was allowed to
equilibrate for 5 minutes and a video was recorded before the next increment in drug
dose. Working concentrations of drugs were prepared fresh on day of experiment, and
diluted in PSS. Arteriolar vasoconstrictor responses were determined from the difference
between measures taken prior drug addition to the PSS (baseline diameter) and at each
drug concentration.

4.2.8.

Statistical analyses and data presentation
Data were analyzed using Sigmastat (Systat Software Inc, San Jose, CA, USA)

and differences were accepted as significantly different at p < 0.05. In order to compare
the effect of sympathetic antagonists on PD arteriolar responses to GM tetanic and
steady-state contractions, one way analysis of variance within each stimulus level was
performed using a Dunnett post test to compare all conditions to the CTRL condition. In
order to compare the effect of sympathetic agonists on CTRL arteriolar responses to GM
tetanic and steady-state contractions, one way analysis of variance within each stimulus
level was performed using a Dunnett post test to compare all conditions to the PD
condition. To determine the effect of arteriolar order on percent change of diameter
following tetanic and rhythmic muscle contraction, a one-way analysis of variance was
used within each condition (i.e., CTRL, PD, PD BIBP3226, PD prazosin and PD
BIBP3226+prazosin) followed by Tukey’s post-hoc comparison test. Differences
between CTRL and PD responses within each concentration of NPY or PE were
compared using unpaired t-tests. Tabular data was also analyzed using unpaired t-tests.
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Summary data are presented as mean values ± standard error (S.E.), unless otherwise
stated.

4.3.
4.3.1.

Results
Characteristics of control and pre-diabetic mice

Body mass and measured fasting blood glucose were greater for PD (42 ± 1 g, 12
± 1 mmol/L) compared to CTRL (23 ± 1 g, 6 ± 1 mmol/L., p < 0.05). Additionally,
reported blood insulin levels were also elevated in PD (~120 ng/mL) compared to CTRL
(<10 ng/mL, Charles River Laboratories, 2006).

4.3.2.

Baseline arteriolar diameter, O2 response and vasodilatory
response to sodium nitroprusside in control and pre-diabetic mice
Baseline 2A, 3A, and 4A diameters were similar between CTRL and PD (Table

4.1). Arteriolar constriction in response to elevating PSS O2 to 21% was also similar
between groups for all arteriolar orders (Table 4.1). Maximal arteriolar diameter elicited
by 10 µM SNP was decreased by 20 ± 3% and 24 ± 4% in PD 2A and 3A respectively,
versus CTRL (Table 4.2, p < 0.05). Maximal dilation at 4A was similar between groups.
Upon adding both sympathetic antagonists BIBP3226 (100 nM) and prazosin (100 nM) to
10 µM SNP superfusion solution, maximal vasodilatory responses of PD 2A and 3A were
no longer different than CTRL arteriolar responses to SNP (Table 4.2).
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Table 4.1. Gluteus maximus arteriolar baseline diameter and responses to elevated
O2 (21%).
2A

Baseline
diameter (µm)
O2 response
(µm)

3A

4A

CTRL

PD

CTRL

PD

CTRL

PD

21 ± 1

22 ± 1

12 ± 1

13 ± 1

7±1

7±1

-6 ± 1

-5 ± 1

-3 ± 1

-4 ± 1

-2.4 ± 0.2

-2.2 ± 0.2

Baseline values were recorded under control conditions (superfusate equilibrated with 5%
CO2–95% N2). O2 response indicates the change in diameter in response to elevating
superfusate O2 from 0 to 21%. Values are mean ± SEM. CTRL, control, n = 6-13; PD,
pre-diabetic, n = 5-12. * p < 0.05 versus CTRL.
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Table 4.2. Maximal diameter responses of gluteus maximus arterioles to sodium
nitroprusside with and without sympathetic receptor blockade (10µM).
Maximal Dilation CTRL

Maximal Dilation PD

Maximal Dilation PD

(SNP; 10 µm)

(SNP; 10 µm)

with sympathetic blockade
(SNP; 10 µm, and
BIBP3226+prazosin; 100µm)

2A

41 ± 1

33 ± 1*

38 ± 2

3A

29 ± 1

22 ± 1*

27 ± 2

4A

18 ± 1

17 ± 1

19 ± 1

Values are mean ± SEM. CTRL, control, n = 6-13; PD, pre-diabetic, n = 3-12. * p < 0.05
versus CTRL.
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4.3.3.

Sympathetic receptor blockade and rapid onset vasodilation in prediabetic mice
Following 400 and 800 ms tetanic contractions, ROV responses of PD were

blunted by 51 ± 6% and 47 ± 6% respectively in 2A, 52 ± 6 % and 62 ± 6% respectively
in 3A, and 58 ± 9% and 59 ± 6% respectively in 4A (Figure 4.1 a, b and c, p <0.05). In
response to 400 ms tetanic contraction, addition of BIBP3226 (Y1R antagonist), prazosin
(α1R antagonist) and BIBP3226 + prazosin to the superfusion solution caused ROV
responses of 2A, 3A and 4A to increase such that responses were no longer different from
CTRL (Figure 4.1 a, b, c). Following 800 ms tetanic contraction, dual sympathetic Y1R
and α1R blockade (BIBP3226 + prazosin) restored 2A ROV responses of PD to that of
CTRL (Figure 4.1 a). Y1R blockade (BIBP3226) and α1R blockade (prazosin) alone
only partially recovered 2A ROV responses of PD (Figure 4.1 a, p < 0.05). For 3A,
prazosin and BIBP3226+prazosin superfusion conditions increased ROV responses of PD
to responses similar to CTRL (Figure 4.1 b); however, BIBP3226 partially recovered the
attenuated vasodilatory response of PD (Figure 4.1 b, p < 0.05). Alternatively in 4A,
BIBP3226 and BIBP3226+prazosin restored ROV to that of CTRL (Figure 4.1 c), where
prazosin alone partially recovered the blunted response (Figure 4.1 c, p < 0.05).

4.3.4.

Sympathetic receptor activation and rapid onset vasodilation in
control mice
In addition to testing the effects of sympathetic receptor blockade on ROV in PD,

we also tested the effects of sympathetic receptor activation on ROV in CTRL. Following
both 400 and 800 ms tetanic contractions, addition of sympathetic agonists NPY (Y1R
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agonist), PE (α1R agonist) or NPY+PE to the superfusion solution decreased ROV
responses of CTRL 2A, 3A and 4A to those of PD (Figure 4.2 a, b, c).

4.3.5.

Sympathetic receptor blockade and spatial arteriolar reactivity in
pre-diabetic mice in response to brief tetanic contraction
Spatial reactivity of ROV responses were investigated based on arteriolar order.

Changes in diameter were normalized to respective baselines and presented as percent
diameter change. As expected, relative ROV responses to 400 and 800 ms tetanic
contractions were attenuated in PD at all arteriolar orders compared to CTRL.
Superfusion of sympathetic antagonists restored relative increases in diameter, so they
were no longer different from CTRL (Figure 4.3).

4.3.5.1.

Effects of sympathetic receptor blockade on relative ROV
responses of 2A, 3A and 4A following 400 ms tetanic contraction

In CTRL, relative increases in diameter were greatest in 4A versus 3A and 2A
(Figure 4.3 a, p < 0.05). In PD, ROV reactivity was also greatest in 4A, but only in
comparison to 2A (Figure 4.3 a, p < 0.05). In PD, BIBP3226 increased relative change in
diameter of 4A specifically, so that 4A responses of PD were different from both 3A and
2A, as demonstrated in CTRL (Figure 4.3 a, p < 0.05). Prazosin also increased ROV
reactivity; however, α1R blockade increased both 3A and 4A responses compared to
responses of 2A (Figure 4.3 a, p < 0.05). Similar to CTRL and effects of BIBP3226,
combination Y1R and α1R blockade (BIBP3226+prazosin condition) caused an increase
in ROV reactivity in PD that was greatest at 4A compared to both 3A and 2A (Figure 4.3
a, p <0.05).

137

4.3.5.2.

Effects of sympathetic receptor blockade on relative ROV
responses of 2A, 3A and 4A following 800ms tetanic contraction

In CTRL, 800ms tetanic contraction elicited robust increases in relative ROV
responses that were greatest in 3A and 4A compared to 2A (Figure 4.3 b, p < 0.05). In
PD, greatest ROV reactivity was only observed at 4A versus 3A and 2A, demonstrating
compromised dilatory reactivity of 3A in PD (Figure 4.3 b, p < 0.05). BIBP3226
increased ROV responses of PD, so that relative increases in diameter were greatest in
both 3A and 4A compared to 2A, as demonstrated in CTRL (Figure 4.3 b, p < 0.05). Both
prazosin and BIBP3226+prazosin conditions caused increases in relative ROV reactivity
of PD that was greatest in 4A versus 3A and 2A, illustrating a greater effect of
sympathetic receptor blockade in most distal arterioles in PD (Figure 4.3 b, p < 0.05).
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Figure 4.1. Sympathetic Y1R and α1R blockade restores ROV in PD.
Data are ROV responses of 2A (a), 3A (b) and 4A (c) following brief tetanic contraction
in CTRL (n=6-12) and PD (n=6-11). BIBP3226 (Y1R antagonist), prazosin (α1R
antagonist) and BIBP3226+prazosin (dual Y1R and α1R blockade) were added to the
superfusion of PD. Sympathetic receptor blockade enhanced ROV of PD to responses
similar to CTRL. * different from CTRL, p < 0.05. CTRL, control; PD, pre-diabetic.
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Figure 4.2. Sympathetic Y1R and α1R activation attenuates ROV in CTRL.
ROV responses of 2A (a), 3A (b) and 4A (c) following brief tetanic contraction in CTRL
(n=6-12) and PD (n=6-11). NPY (Y1R agonist), PE (α1R agonist) and NPY+PE (dual
Y1R and α1R activation) were added to the superfusion of PD. Sympathetic receptor
activation decreased ROV of CTRL to responses similar to PD. * different from PD, p <
0.05. CTRL, control; PD, pre-diabetic.
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Figure 4.3. Effects of Y1R and α1R blockade on arteriolar branch order ROV
responses following tetanic contraction in PD.
Percent change in diameter following brief 400 ms (a) and 800 ms (b) tetanic
contractions. Following both contractions, the percent change in diameter was attenuated
in PD (n= 5-11) compared to CTRL (n=6-12) at 2A, 3A and 4A. Superfusion of
sympathetic receptor antagonists BIBP3226 and prazosin caused increases in percent
diameter change in PD, affecting relative changes of contraction-evoked dilation in distal
arterioles the greatest. * Different vs. CTRL, p < 0.05; # different vs. responses of other
arterioles within condition, p < 0.05;  Different vs. 2A response within condition, p <
0.05. CTRL, control; PD, pre-diabetic.
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4.3.6.

Sympathetic receptor blockade and steady-state vasodilation to
rhythmic contraction in pre-diabetic mice
Following 2 and 8Hz rhythmic contractions, vasodilatory responses of PD were

blunted by 46 ± 9% and 47 ± 7% respectively in 2A, 60 ± 7% and 44 ± 9% respectively
in 3A, and 32 ± 11% and 53 ± 11% respectively in 4A (Figure 4.4 a, b and c, p <0.05). In
response to 2 Hz rhythmic contraction, vasodilation of 2A in PD was moderately
increased with the addition of BIBP3226 to the superfusion (Figure 4.4 a, p < 0.05),
however prazosin and BIBP3226 + prazosin superfusion conditions increased 2A
vasodilation such that responses were no longer different from CTRL (Figure 4.4 a). For
3A, addition of BIBP3226+prazosin to the superfusion also caused an increase in
vasodilatory responses to 2 Hz contraction in PD, where diameter change was no longer
different to that of CTRL (Figure 4.4 b). BIBP3226 and prazosin alone caused a modest
increase in diameter change, however responses were not similar to that of CTRL (Figure
4.4 b, p < 0.05). For 4A, superfusion of BIBP3226, prazosin and BIBP3226+prazosin
increased PD vasodilatory responses to 2 Hz rhythmic contraction to that of CTRL
(Figure 4.4 c). Following 8 Hz rhythmic contraction, vasodilation of PD 2A, 3A and 4A
were

increased

with

all

three

superfusion

conditions

(BIBP3226,

prazosin,

BIBP3226+prazosin), where diameter changes were similar to CTRL (Figure 4. 4 a, b
and c).

4.3.7.

Sympathetic receptor activation and steady-state vasodilation to
rhythmic contraction in control mice
Sympathetic Y1R and α1R agonists were also added to the superfusion of CTRL

experiments to attenuate CTRL arteriolar vasodilatory responses to rhythmic contractions
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(Figure 4.5). Superfusion of NPY, PE and NPY+PE in CTRL decreased vasodilation of
2A, 3A and 4A to 2 and 8 Hz rhythmic contractions so that diameter changes were
similar to PD (Figure 4.5 a, b and c).

4.3.8.

Sympathetic receptor blockade and spatial arteriolar reactivity in
pre-diabetic mice in response to rhythmic contraction
Spatial reactivity of steady-state vasodilatory responses to rhythmic contraction

was also investigated based on arteriolar order. Changes in diameter were normalized to
respective baselines and presented as percent diameter change. Following 2 Hz rhythmic
contraction, relative diameter change was decreased in 2A and 3A of PD, where 4A
responses were similar to CTRL. Sympathetic blockade of Y1R, α1R, and both Y1R and
α1R increased relative dilatory responses of PD in 2A, however only dual Y1R and α1R
blockade increased relative vasodilatory reactivity of 3A (Figure 4.6 a). Following 8 Hz
rhythmic contraction however, attenuated dilatory reactivity observed in PD was
increased to dilatory responses similar to CTRL in all arterioles, for all conditions of
sympathetic receptor blockade (Figure 4.6).

4.3.8.1.

Effects of sympathetic receptor blockade on relative dilatory
responses of 2A, 3A and 4A following 2 Hz rhythmic contraction

In CTRL, relative increases in diameter were greatest in 4A and 3A compared to
2A (Figure 4.6 a, p < 0.05). In PD, only 4A responses were greatest compared to 3A and
2A, demonstrating compromised dilatory reactivity of 3A in PD (Figure 4.6 a, p < 0.05).
BIBP3226 increased relative vasodilatory responses of PD so that responses of both 4A
and 3A were greater than 2A (Figure 4.6 a, p < 0.05). Prazosin elicited increases in 4A
vasodilatory responses in PD, where relative increases in diameter were greater than 3A
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and 2A (Figure 4.6 a, p < 0.05). Similar to the effects of BIBP3226 and responses of
CTRL, dual Y1R and α1R blockade increased relative dilatory responses of PD in both
3A and 4A compared to 2A (Figure 4.6 a, p < 0.05).

4.3.8.2.

Effects of sympathetic receptor blockade on relative dilatory
responses of 2A, 3A and 4A following 8Hz rhythmic contraction

In CTRL, relative increases in diameter were greatest in 4A compared to 2A
(Figure 4.6 a, p < 0.05). Similarly in PD, although reduced in magnitude, 4A responses
were greatest compared to 2A (Figure 4.6 b, p < 0.05). BIBP3226 and prazosin
conditions increased the magnitude of relative dilatory responses of PD, where effects of
Y1R and α1R blockade evoked greatest relative changes in diameter in 4A versus 2A
(Figure 4.6 b, p < 0.05). Dual sympathetic Y1R and α1R blockade elicited increases in
relative vasodilatory responses in PD that were greater in 3A and 4A compared to 2A,
demonstrating a greater contribution of both Y1R and α1R activation to attenuated
dilatory responses of 3A and 4A in PD (Figure 4.6 b, p < 0.05).
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Figure 4.4. Sympathetic Y1R and α1R blockade restores steady-state vasodilation in
PD.
Data are maximal dilatory responses of 2A (a), 3A (b) and 4A (c) following 30 seconds
of rhythmic twitch contractions in CTRL (n=7-12) and PD (n=6-11). BIBP3226 (Y1R
antagonist), prazosin (α1R antagonist) and BIBP3226+prazosin (dual Y1R and α1R
blockade) were added to superfusion of PD. Sympathetic receptor blockade enhanced
dilatory responses to rhythmic contractions of PD to responses similar to CTRL. *
different from CTRL, p < 0.05. CTRL, control; PD, pre-diabetic.
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Figure 4.5. Sympathetic Y1R and α1R activation attenuates steady-state
vasodilation in CTRL.
Data are maximal dilatory responses of 2A (a), 3A (b) and 4A (c) following 30 seconds
of rhythmic twitch contractions in CTRL (n=7-12) and PD (n=6-11). NPY (Y1R agonist),
PE (α1R agonist) and (dual Y1R and α1R activation) were added to the superfusion of
PD. Sympathetic receptor activation decreased ROV of CTRL to responses similar to PD
compared to CTRL. * different from PD, p < 0.05. CTRL, control; PD, pre-diabetic.
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Figure 4.6. Effects of Y1R and α1R blockade on arteriolar branch order dilatory
responses following sustained rhythmic contraction in PD.
Percent change in diameter following 30 seconds of sustained rhythmic contraction at 2
Hz (a) and 8 Hz (b) tetanic contractions. The percent change in diameter was attenuated
in PD (n= 6-11) compared to CTRL (n=7-12) at 2A, 3A and 4A, however not in 4A
following 2 Hz contraction. Superfusion of sympathetic receptor antagonists BIBP3226
and prazosin caused increases in percent diameter change in PD, affecting relative
changes of contraction-evoked dilation in distal arterioles the greatest. * Different vs.
CTRL, p < 0.05; # different vs. responses of other arterioles within condition, p < 0.05; 
Different vs. 2A response within condition, p < 0.05. CTRL, control; PD, pre-diabetic.
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4.3.9.

Arteriolar reactivity to sympathetic Y1R and α1R activation
Increasing concentrations of Y1R agonist NPY (10-13-10-8 M) within the

superfusion led to decreases in arteriolar diameter in both CTRL and PD groups (Figure
4.7). Vasoconstrictor responses of 2A to NPY doses were greater in PD versus CTRL,
especially at NPY 10-11 M (Figure 4.7 a, p < 0.05). For 3A, vasoconstrictor responses
were also greater in PD versus CTRL, especially for NPY doses of 10-11 – 10-8 M (Figure
4.7 b, p < 0.05). For 4A, vasoconstrictor responses were similar between groups, however
at the highest dose of NPY (10-8 M), PD vasoconstrictor responses were greater than
those of CTRL (Figure 4.7 c, p < 0.05).
Increasing concentrations of α1R agonist PE (10-9-10-5 M) in the superfusion also
led to decreases in arteriolar diameter in both CTRL and PD groups (Figure 4.8).
Vasoconstrictor responses of 2A were similar between groups for all PE doses. For 3A
and 4A however, vasoconstrictor responses of CTRL and PD were similar for PE doses
10-9-10-6 M, however at 10-5 M, vasoconstrictor responses of PD were greater than CTRL
(Figure 4.8 b and c, p < 0.05).
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Figure 4.7. Vasoconstriction of gluteus maximus arterioles to NPY.
2A (a), 3A (b) and 4A (c) vasoconstrictor responses to increasing doses of NPY (Y1R
agonist) in CTRL (n=7-8) and PD (n=5-7). * different from CTRL within drug dose, p <
0.05. CTRL, control; PD, pre-diabetic.
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Figure 4.8. Vasoconstriction of gluteus maximus arterioles to PE.
2A (a), 3A (b) and 4A (c) vasoconstrictor responses to increasing doses of PE (α1R
agonist) in CTRL (n=5-9) and PD (n=5-7). * different from CTRL within drug dose, p <
0.05. CTRL, control; PD, pre-diabetic.
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4.4.

Discussion

Our group has recently demonstrated that pre-diabetes compromises contractionevoked vasodilation of skeletal muscle arterioles. Prior to this study, we also identified
heightened sympathetic regulation of basal vascular tone in pre-diabetic ZDF rats
(Novielli et al., 2012). Therefore, in this study, we sought to determine whether enhanced
sympathetic Y1R and α1R receptor activation of skeletal muscle arterioles contributes to
decrements in contraction-evoked vasodilation in pre-diabetes. Congruent with our
hypotheses, we demonstrated that inhibition of Y1Rs and α1Rs with BIBP3226 and
prazosin increased contraction-evoked vasodilatory responses to levels similar to CTRL.
Conversely, blunted contraction-evoked vasodilation observed in PD was reproduced in
CTRL via activation of Y1Rs and α1Rs with NPY and PE. Sympathetic receptor
blockade also restored spatially-dependent differences in contraction-evoked vasodilation
between arteriolar orders in PD, increasing relative dilatory responses of distal
vasculature. In addition, arteriolar vasoconstrictor responsiveness to sympathetic receptor
agonists (NPY and PE) appeared to be greater at in PD compared to CTRL, especially at
higher concentrations. These findings suggest that Y1R and α1R activation are enhanced
in pre-diabetes, resulting in deficits in arteriolar vasodilation to skeletal muscle
contraction.

4.4.1.

Sympathetic Y1R- and α1R-mediated effects on contractionevoked arteriolar vasodilation in pre-diabetic mice
Rapid onset vasodilation results in the immediate hyperemic response elicited

within seconds of muscle contraction at exercise onset. This almost-instantaneous
vascular response has been well established in humans and within animal
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microcirculatory models (M. L. Armstrong, Dua, & Murrant, 2007; Corcondilas,
Koroxenidis, & Shepherd, 1964; Jackson et al., 2010; Kirby, Carlson, Markwald, Voyles,
& Dinenno, 2007; Marshall & Tandon, 1984; Mihok & Murrant, 2004; Shoemaker,
Tschakovsky, & Hughson, 1998; Tschakovsky et al., 2004; VanTeeffelen & Segal,
2006), and thus is a conserved response in initiating rest-to-exercise transitions to
metabolic demand. Until recently, no studies have investigated ROV responses in prediabetes. In our most recent study, as well as in the current study, we consistently
demonstrated blunted arteriolar ROV responses of 50% or greater following brief tetanic
muscle contraction in the GM of pre-diabetic mice, with no differences in baseline
arteriolar diameter. When GM arterioles of PD were superfused with sympathetic Y1R
antagonist BIBP3226, and α1R antagonist prazosin, attenuated ROV responses were
restored to levels observed in CTRL. Increased ROV responses of PD arterioles
following sympathetic blockade prompted experiments testing whether sympathetic
activation could do the opposite in CTRL. Without modification of baseline arteriolar
diameter, modest activation of Y1R and α1R with NPY and PE reduced ROV responses
of CTRL arterioles following tetanic contraction similar to attenuated responses observed
in PD. These novel findings indicate a constitutively higher level of arteriolar smooth
muscle cell Y1R and α1R activation in skeletal muscle microvasculature of pre-diabetic
mice, which likely impinge on existing dilatory mechanisms. Past studies of the
microcirculation in the hamster cremaster muscle have demonstrated a contributing role
of potassium and adenosine to rapid vasodilatory responses elicited by brief tetanic
contractions (M. L. Armstrong et al., 2007, Ross, Mihok & Murrant, 2013). In prediabetic mice, increased levels of Y1R and α1R activation, may restrict potassium-
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and/or adenosine- mediated VSMC hyperpolarization, thus attenuating ROV to brief
tetanic muscle contraction.
Contrary to brief tetanic contraction, sustained rhythmic muscle contraction
evokes a progressive increase in arteriolar diameter and blood flow based on the
metabolic demands of the tissue (R. B. Armstrong & Laughlin, 1985; Bockman, 1983;
Mohrman & Regal, 1988). Studies investigating mechanisms contributing to sustained
vasodilation throughout bouts of muscle contraction have identified that the production of
local vasoactive metabolites from skeletal muscle tissue and the vasculature contribute to
this response (Clifford & Hellsten, 2004). As these signaling events differ from those
involved in ROV (Clifford & Hellsten, 2004; Haddy & Scott, 1975; Wunsch, MullerDelp, & Delp, 2000), it was not known whether decrements in contraction-evoked
steady-state dilation, previously demonstrated in PD, was a result of sympatheticallymediated vasoconstriction. In the current study, up to a 60% reduction in steady-state
dilation following 30 seconds of rhythmic twitch contractions was observed in PD. Upon
sympathetic Y1R and α1R blockade, arteriolar vasodilatory responses of PD were again
restored to levels of CTRL. All sympathetic antagonist conditions were especially
effective in restoring PD vasodilatory responses following the greatest contraction
frequency (8 Hz). Contrasting experiments determined that activation of arteriolar Y1R
and α1R in CTRL caused decreases in contraction-evoked vasodilatory responses, in turn
resembling responses of PD. These findings further demonstrate that increased levels of
arteriolar Y1R and α1R activation in pre-diabetes can restrain vasodilatory responses
regardless of the nature of contractile activity.
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Blockade of arteriolar Y1R and α1R activation consistently increased ROV and
steady-state vasodilatory responses to respective tetanic and rhythmic contractions across
arterioles. Despite the observed ‘gain of function’, blockade of Y1R or α1R
independently was not always successful in completely restoring contraction-evoked
dilatory responses so that they were no longer different than CTRL. ROV responses
following 400 ms tetanic contractions were fully restored at all arteriolar orders for all
sympathetic antagonist conditions. For longer tetanic contractions (800 ms), evoking
greater dilatory responses, 2A ROV could not be restored via independent receptor
blockade in PD, where α1R blockade alone restored ROV of 3A, and Y1R blockade
alone restored ROV responses of 4A. Following low frequency rhythmic contractions,
2A dilation of PD was not fully restored via independent Y1R blockade, and 3A dilation
was not fully restored via independent blockade of both Y1R and α1R. Inability to
increase ROV or steady-state dilation by blocking sympathetic receptors independently
may be due to the vasoconstrictive effects of the outstanding active sympathetic receptor.
Interestingly, PD demonstrated elevated arteriolar vasoconstrictor responsiveness to
increasing doses of Y1R and α1R agonists, NPY and PE. These data may suggest greater
vasoconstrictive effects of sympathetic receptor activation themselves, or greater vascular
expression of sympathetic receptors, as demonstrated previously in the hindlimb of prediabetic ZDF rats (Novielli et al., 2012). A potential increase in arteriolar sympathetic
receptor density along with reported increases in SNA associated with pre-diabetes may
impinge on contraction-evoked dilatory responses in PD, despite blockade of sympathetic
receptors independently. Following 8 Hz tetanic contraction, however, all sympathetic
antagonist conditions (independent and dual blockade) elicited robust increases in steady-
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state vasodilation in PD, similar to levels of CTRL. In conjunction with sympathetic
receptor blockade, large accumulation of vasoactive metabolites in response to high
frequency muscle contraction likely contributes to the significant increase of arteriolar
diameter in PD. As expected however, dual receptor blockade recovered ROV and
steady-state vasodilatory responses of PD following all tetanic and rhythmic contractions,
at all arteriolar orders studied. Interaction between Y1R and α1R activation has been
established, where NPY and NE can act together to cause greater vasoconstriction
compared to responses elicited alone, especially under conditions of increased
sympathetic activation (Dahlof, Dahlof, & Lundberg, 1985; Jackson et al., 2005;
Revington & McCloskey, 1988). Independent of exercise, we also investigated maximal
arteriolar vasodilatory responses elicited by GM superfusion of SNP. We demonstrated
decreased arteriolar dilation to SNP in PD, however this response was restored following
dual blockade of Y1R and α1R in the presence of SNP. These findings suggest that
endogenous vasodilatory mechanisms contributing to dilation during muscle contraction,
as well as direct smooth muscle cell relaxation, can be disrupted by constitutively
enhanced dual Y1R and α1R activation in pre-diabetes.

4.4.2.

Emphasis on NPY-mediated neurovascular modulation in prediabetes
This is the first study to demonstrate sympathetically-mediated reductions of both

ROV and steady-state dilation of arterioles in pre-diabetes. In conditions such as aging
and the metabolic syndrome, studies investigated whether decrements in functional
hyperemia and vasodilatory responses following muscle contraction was a result of
enhanced α-adrenergic modulation of vascular responses (Casey & Joyner, 2012;
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Dinenno, Masuki, & Joyner, 2005; Frisbee, 2004; Jackson et al., 2010; Naik, Xiang,
Hodnett, & Hester, 2008). In accordance with findings of the current study, α-adrenergic
receptor blockade resulted in increased contraction-evoked vasodilation in aged and
obese groups. Conversely, peptidergic-mediated modulation of contraction-evoked
vasodilation was not considered. In addition to NE, it is well recognized that NPY
contributes to sympathetically-mediated vascular regulation at rest, as well as during
muscle contraction (Buckwalter, Hamann, & Clifford, 2005; Buckwalter, Hamann,
Kluess, & Clifford, 2004; DeLorey et al.; Evanson et al.; Jackson et al., 2005; Jackson et
al., 2004; Novielli et al., 2012). Under conditions of greater SNA, neuronal NPY release
and its effects on arteriolar constriction become more apparent (Bartfai, Iverfeldt, Fisone,
& Serfozo, 1988; De Camilli & Jahn, 1990; Lundberg, Franco-Cereceda, Lou, Modin, &
Pernow, 1994). Therefore greater NPY-mediated Y1R vasoconstrictor restraint on
contraction-evoked vasodilatory responses was anticipated in pre-diabetic mice of the
present study.

4.4.3.

Spatially-dependent arteriolar dilation and sympathetic receptor
blockade
Skeletal muscle contraction elicits vasodilatory responses that differ based on the

location of the arteriole within the microvascular network, where proportional increases
in vasodilation are greatest in smaller distal arterioles compared to proximal larger
arterioles (Dodd & Johnson, 1991; Marshall & Tandon, 1984; VanTeeffelen & Segal,
2006). This was demonstrated in the current study, where in CTRL, ROV and steadystate dilatory reactivity to tetanic and rhythmic muscle contraction was greatest in distal
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arterioles (4A and 3A). In PD, however, spatially-dependent arteriolar responses were
almost indistinguishable, where relative diameter changes of only 4A were affected by
both types of muscle contraction. In turn, sympathetic receptor antagonist conditions
elicited increases in relative diameter responses, restoring appropriate arteriolar reactivity
from distal to proximal arterioles. Interestingly, effects of each sympathetic antagonist
condition differed between arteriolar orders. Within-condition differences between
arterioles in PD may suggest heterogeneous Y1R and α1R-mediated attenuation of
contraction-evoked dilation throughout the arteriolar network. This may be a result of
differences in sympathetic receptor distribution or differences in neural innervation
density at the distal microvasculature (Cowley & Franchini, 1996). It has been confirmed
that α-adrenergic receptor subtype distribution in arteriolar networks in the mouse GM
varies with vessel branch order, where α1Rs are located more distally (Moore, Jackson,
& Segal, 2010). Additionally, studies of feline skeletal muscle microvasculature
demonstrated that NPYs vasoconstrictor effects are greatest at distal arterioles (Ekelund
& Erlinge, 1997). Thus we expected sympathetic receptor blockade to affect vasodilatory
responses of distal arterioles in PD.

4.4.4.

Experimental considerations
In the current study, we investigated whether constitutively enhanced arteriolar

Y1R and α1R activation contributed to decrements in contraction-evoked vasodilation in
pre-diabetic mice. The use of BIBP3226 and prazosin allowed us to specifically block
Y1R and α1R, therefore the effects of endogenous NPY and norepinephrine (NE) on
arteriolar modulation of dilatory responses could be resolved in pre-diabetes. Although α
2-adrenergic receptors (α2R) and NPY Y2 receptors (Y2R) are present post-junctionally
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on the vasculature and contribute to sympathetically-mediated vasoconstriction (Jie, van
Brummelen, Vermey, Timmermans, & van Zwieten, 1984; Kiowski, Hulthen, Ritz, &
Buhler, 1983), they are also located pre-junctionally and modulate NE and NPY release
via a negative feedback mechanism (Ruffolo, Nichols, Stadel, & Hieble, 1991;
Wahlestedt et al., 1990). In order to reduce potentially confounding effects of pre- and
post- junstional α2R and Y2R activity on sympathetic vascular modulation in prediabetes, we investigated α1R- and Y1R- mediated effects, as it is understood that they
are located post-junctionally on VSMCs. In addition, a recent study has demonstrated
heterogeneous distribution of α-adrenergic receptor subtypes throughout the arteriolar
network of the mouse GM. It was observed that distal arterioles (e.g. 3As) exhibited the
greatest vasoconstrictor responses to α1R agonist PE, confirming a greater contribution
of α1Rs to sympathetic vascular control in the arterioles examined in the current study.
Vasoconstriction elicited by the α2R agonist UK14304 was greatest in 1As, an area of
the arteriolar tree we did not directly examine in the current study. Although there are no
studies characterizing NPY Y receptor distribution throughout microvascular networks,
past experiments have demonstrated greater affects of Y1R-mediated vasoconstriction
compared to Y2Rs in distal vasculature of cat hindlimb skeletal muscle (Ekelund &
Erlinge, 1997). Therefore we feel that increased sympathetic activity at the level of
skeletal muscle arterioles in pre-diabetic mice is predominantly an affect of enhanced
Y1R and α1R activation.
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4.5.

Conclusions

In the current study, we demonstrated that ROV and steady-state vasodilation in
response to tetanic and rhythmic muscle contraction were blunted in branching arterioles
of the GM in pre-diabetic mice. Since Y1R and α1R blockade restored contractionevoked vasodilatory responses in PD, and Y1R and α1R activation attenuated
contraction-evoked vasodilatory responses in CTRL, our data suggest that pre-diabetes is
associated with greater sympathetic modulation of arteriolar function via elevated levels
of Y1R and α1R activation. Furthermore, disrupted spatial reactivity of PD vasodilatory
responses to muscle contraction was also restored following superfusion of sympathetic
Y1R and α1R antagonists, increasing relative diameter changes of distal arterioles. In
addition, VSMC relaxation elicited by superfusion of SNP was also attenuated in
arterioles of PD, where dual Y1R and α1R blockade in the presence of SNP increased
maximal arteriolar dilatory responses of PD to levels similar to CTRL. The present study
provides evidence that pre-diabetes is associated with microvascular impairments related
to increased sympathetic receptor activation throughout skeletal muscle branching
arteriolar networks.
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Chapter 5 : Conclusions
5.1.

Summary

The novel findings presented in this thesis contribute to the understanding of vascular
dysfunction associated with type 2 diabetic disease progression. Specifically, in prediabetes, elevated sympathetic microvascular modulation leads to compromised blood
flow regulation in skeletal muscle. The presented studies demonstrate that pre-diabetes
promotes an overall increase in basal Y1R and α1R vascular control in skeletal muscle
under resting and active conditions. These studies are also the first to address the impact
of augmented peptidergic (neuropeptide Y, NPY) contribution, in addition to
noradrenergic contribution, to skeletal muscle vascular dysfunction under resting and
active conditions in pre-diabetes. In support of hypothesis 1, it was shown that chronic
basal activation of NPY Y1 receptor (Y1R) and α1 adrenergic receptor (α1R) was
elevated in hindlimb vasculature of pre-diabetic Zucker diabetic fatty (ZDF) rats. In
addition, expression of hindlimb tissue NPY and vascular Y1R and α1R was greater in
pre-diabetic compared to control rats, demonstrating changes in sympathetic control
system components involved in vascular modulation. These data support heightened
sympathetic nerve activity (SNA) associated with pre-diabetes, thus providing impetus
for subsequent studies investigating the impact of pre-diabetes and elevated sympathetic
receptor activation on skeletal muscle microvascular function.
In contrast to experiments carried out under basal conditions in chapter 2, the
experiments of chapter 3 investigated the impact of pre-diabetes on microvascular
function in contracting muscle. Using a murine model of pre-diabetes, an adaptation of
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the previously established gluteus maximus preparation, and intravital microscopy
techniques, experiments from chapter 3 supported hypothesis 2, where arteriolar dilation
and blood flow in response to skeletal muscle contraction was blunted in pre-diabetic
mice, compared to healthy controls. Analysis of contraction-evoked arteriolar responses
throughout continuous branching arterioles also uncovered spatially-dependent changes
in arteriolar diameter, where relative dilation of distal arterioles was greater than that of
proximal arterioles. In pre-diabetic mice however, this pattern of dilation was disrupted
compared to control. In chapter 4, we determined whether elevated sympathetic
modulation of vascular control contributed to impaired contraction evoked dilation in
pre-diabetic mice. Findings from chapter 4 supported hypothesis 3, as we found that
attenuated arteriolar responses to skeletal muscle contraction were a result of enhanced
constitutive activation of arteriolar Y1R and α1R in pre-diabetic mice. Additionally,
arteriolar vasoconstrictor responsiveness to sympathetic Y1R and α1R activation was
greater in pre-diabetic mice.

5.2.

Merit

The findings of this thesis contribute to further understanding cardiovascular comorbidities associated with diabetic disease progression. Past research has generally
focused on microvascular disease as a result of prolonged chronic diabetic conditions.
Few studies however, have examined the impact of early pre-diabetes on microvascular
function within skeletal muscle. The studies presented herein demonstrate that pre-
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diabetes is accompanied by augmented peripheral sympathetic vascular modulation of
basal vascular tone and vasodilatory responses to muscle contraction.
Prior to studies performed in this thesis, no previous studies have examined
peptidergic vascular control in pre-diabetes, overt type 2 diabetes or any other metabolic
condition (i.e., obesity, hypertension, the metabolic syndrome). Sympathetic modulation
of skeletal muscle vasculature in health and disease is often examined in light of
noradrenergic mechanisms (Frisbee, 2003, 2004; Hodnett, Xiang, Dearman, Carter, &
Hester, 2008; Lesniewski et al., 2008; Naik, Xiang, & Hester, 2006; Naik, Xiang,
Hodnett, & Hester, 2008; Okon, Szado, Laher, McManus, & van Breemen, 2003;
Romanko, Ali, Mintz, & Stepp, 2009; Stepp & Frisbee, 2002). Notably, NPYs role in
sympathetic vascular regulation within skeletal muscle has been demonstrated under
basal resting and active conditions (Buckwalter, Hamann, & Clifford, 2005; Buckwalter,
Hamann, Kluess, & Clifford, 2004; DeLorey et al., 2010; Evanson et al., 2012; Jackson,
Milne, Noble, & Shoemaker, 2005a; Jackson, Noble, & Shoemaker, 2004; Novielli, AlKhazraji, Medeiros, Goldman, & Jackson, 2012). Increased SNA accompanying prediabetes supports a greater role of NPY in sympathetic vascular modulation. NPY release
is understood to increase under such conditions [in conjunction with norepinephrine
(NE)], and its influence on sympathetic vasoconstrictor effects of arterioles become
greater (Bartfai, Iverfeldt, Fisone, & Serfozo, 1988; De Camilli & Jahn, 1990; Lundberg,
Franco-Cereceda, Lou, Modin, & Pernow, 1994). Experimental findings from chapters 2
and 4 highlight the role of NPY in augmented skeletal muscle vascular control, whereby
NPYs contribution to sympathetic regulation of skeletal muscle blood flow and arteriolar
diameter was increased in pre-diabetic rats and mice. Therefore, studies examining
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sympathetic vascular control mechanisms should consider consequences of NPY-Y1R
activation in addition to α-adrenergic mechanisms.
Functional experiments conducted in chapters 2, 3 and 4 were performed in vivo
with the use of rat and mouse models of pre-diabetes. Using an in vivo approach provided
the ability to evaluate vascular function within the animal itself, leaving endogenous
neural and vascular control mechanisms intact. In chapter 2, in vivo blood flow
measurements were evaluated at the level of the femoral artery in pre-diabetic ZDF and
control rats. Under basal conditions, changes in resting blood flow that were evoked by
sympathetic receptor blockade provided a summation of the modifications in downstream
resistance within branching microvascular networks of hindlimb skeletal muscle. In
chapters 3 and 4 however, the in vivo experimental approach was extended into the
skeletal muscle microvasculture of the gluteus maximus (GM) in pre-diabetic and healthy
mice. Intravital microscopy served to directly assess functional responses of arterioles
themselves, where physiological interactions between microvessels, muscle fibers and
perivascular neural control could be resolved. The planar geometry and uniform thinness
of the GM enables access to its entire microvascular network for imaging and
experimental perturbations, where diameter and blood flow measurements (Al-Khazraji,
Novielli, Goldman, Medeiros, & Jackson, 2012) can be made within one focal plane. As
such, arteriolar responses to both tetanic and rhythmic muscle contraction were evaluated
at multiple orders of arterioles. Development of this model was ideal for investigating the
impact of early pre-diabetes on arteriolar network regulation in skeletal muscle. This
model can be used to address additional regulatory events of the microvasculature that
may be compromised in early pre-diabetes.
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The use of experimental preparations used in chapters 2, and 3 and 4 allowed for
in situ evaluation of sympathetic Y1R and α1R effects on vascular control. With the use
of specific Y1R and α1R antagonists, BIBP3226 and prazosin, autogenous sympathetic
receptor-ligand mediated effects were uncovered in chapters 2 and 4. In a contrasting
manner, the use of Y1R and α1R agonists (chapter 4) may determine the existence of
receptors and outcomes of receptor activation (i.e. induce vasoconstriction), or activate
sympathetic receptors to modify physiological outcomes (i.e. blunting of contractionevoked arteriolar dilation in control mice). Targeting Y1R and α1R pharmacologically
with the use of antagonists and agonists therefore provided the ability to discern
differences in sympathetic vascular control between pre-diabetic and control groups that
may have thereby been overlooked, as resting cardiovascular and hemodynamic
characteristics were similar between experimental groups.

5.3.

Limitations and assumptions

The experiments presented in this thesis have been conducted using rodent models of
pre-diabetes, thus limitations may arise when translating results to pre-diabetic humans.
Heightened SNA has been observed in pre-diabetic individuals affected by insulin
resistance and hyperinsulinemia, however sympathetically-mediated modulation of
vascular function remains to be investigated in pre-diabetic humans. Nevertheless, animal
models are essential to answering research questions pertaining to physiological
processes in health and disease. The ZDF rat expresses a dysfunctional leptin receptor,
thus leptin cannot interact with its respective receptor to suppress appetite. When male
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ZDF rats are fed a high-fat diet, they develop obesity, insulin resistance, and
hyperinsulinemia, and ultimately become full blown diabetic (Lesniewski et al., 2008;
Oltman et al., 2006). The ZDF rat represents a model of type 2 diabetic disease
progression, where it exhibits a pre-diabetic period, followed by genetically predisposed
development of overt type 2 diabetes and pancreatic failure (Etgen & Oldham, 2000).
The rat model used in chapter 2 represented the pre-diabetic condition at 7 weeks of age,
sharing similar pathological metabolic characteristics to pre-diabetic humans e.g. marked
increases in circulating plasma insulin, insulin resistance, elevated blood glucose, obesity
(Kim & Reaven, 2008a, 2008b; Lyssenko et al., 2005). Additionally, the rat is the most
commonly used species in cardiovascular research, and is characterized by sympathetic
nervous system responses and components similar to humans (Montano, Furlan, Guzzetti,
McAllen, & Julien, 2009). The pre-diabetic ZDF rat model used in chapter 2 was
therefore appropriate to study the impact of pre-diabetes on basal sympathetic vascular
modulation of skeletal muscle blood flow.
In chapters 3 and 4, studies were performed using a mouse model of pre-diabetes
(the Pound Mouse) of the c57bl6 background, exhibiting the same leptin receptor
mutation as the pre-diabetic ZDF rat, as well as similar pathological metabolic
characteristics to the pre-diabetic rat and human condition (Lee & Cox, 2011).
Conversely however, the pre-diabetic Pound Mouse is not genetically predisposed to
developing type 2 diabetes, and therefore does not pose an age restriction on
experimental procedures. Previous studies have used the c57bl6 mouse to evaluate
sympathetic control mechanisms of arteriolar function in the gluteus maximus (Bearden,
Payne, Chisty, & Segal, 2004; Jackson, Moore, & Segal, 2010; Moore, Bearden, & Segal,
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2010; Moore, Jackson, & Segal, 2010), thus we adapted this skeletal muscle preparation
to the pre-diabetic model used in chapters 3 and 4. Although not demonstrated in prediabetes, mouse versus human comparisons of vascular function have been highlighted in
ageing studies. In aged mice, impaired hemodynamic and arteriolar dilatory responses to
contraction of the gluteus maximus muscle was a result of enhanced sympathetic receptor
activation (Jackson et al., 2010). Accordingly, aged humans demonstrate elevated SNA,
which has also been demonstrated to restrict blood flow responses to exercising limbs
(Casey & Joyner, 2012; Dinenno & Joyner, 2006; Proctor & Parker, 2006). Findings of
chapter 4 demonstrated that enhanced sympathetic receptor activation throughout the
microvasculature of the GM results in blunted dilatory responses to muscle contraction in
pre-diabetic mice, however this has not been confirmed in humans. Humans affected by
insulin resistance or pre-diabetes have indeed demonstrated instances of heightened SNA
and impaired functional hyperemic responses to muscle contraction on separate accounts.
Based on the findings of this thesis, increased SNA likely contributes to attenuated
vascular responses to muscle contraction in pre-diabetic humans, however this remains to
be elucidated.
Although it was not measured directly, sympathetic activity was assumed to be
elevated in pre-diabetic animals used in studies of this thesis. Experiments were
conducted in anesthetized animals, and therefore concerns may be raised regarding the
effects of anesthesia on cardiovascular and sympathetic systems. Barbiturates are often
used for rodent anesthesia for invasive non-recovery procedures, however prolonged
anesthesia and supplemental doses may induce respiratory and cardiovascular depression.
The majority of experimental variables within this thesis concerned cardiovascular
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measurements. Therefore the appropriate anesthetic that was used for all animals was a
cocktail of α-chloralose and urethane. Both α-chloralose and urethane are able to produce
long periods of anesthesia, without jeopardizing cardiopulmonary reflexes. Additionally,
blood pressure and respiration are not affected, and spinal and baroreceptor reflexes
remain intact (Jackson, Milne, Noble, & Shoemaker, 2005b; Jackson et al., 2004; Killip,
1963; Soma, 1983). Experimental outcomes of experiments were therefore determined
with confidence that the anesthetic did not confound the validity of cardiovascular
measurements obtained in studies of chapters 2, 3, and 4.

5.4.

Future Directions

As pre-diabetes affects one quarter of the North American population, dietary
modification and increased activity level have become the primary first line of defense
against diabetic disease progression. Compliance to such lifestyle changes, specifically
increased physical activity, may be low as a result of compromised perfusion of
contracting muscle. Insufficient blood flow distribution and supply to working tissues
may interfere with muscle performance and may even become painful in extreme
conditions. Further investigations using animal models to address microvascular function
in pre-diabetes may uncover additional functional mechanisms that may be compromised.
In contracting skeletal muscle, vasodilation can ascend the arteriolar network
(Hilton, 1959). Vasodilation is generally initiated at distal arterioles and travels
proximally past intramuscular arterioles, decreasing vascular resistance and increasing
blood supply to arteriolar networks of working muscle (Folkow, Sonnenschein, &

175
Wright, 1971; Segal & Jacobs, 2001). Increased SNA has been shown to inhibit the
spread of dilation along arterioles and feed arteries (Haug & Segal, 2005; Haug, Welsh,
& Segal, 2003; Kurjiaka & Segal, 1995), and thus attenuates conducted vasodilatory
responses within arteriolar networks (VanTeeffelen & Segal, 2003). Increased SNA in
the pre-diabetic condition may therefore compromise conducted vasodilatory responses,
in addition to maximal arteriolar dilatory responses to exercise. Future studies can utilize
the arteriolar network of the GM to evaluate the spread of dilation initiated at distal precapillary arterioles and propagated upstream. Micropipette pressure pulse ejection of
vasoactive substances can be delivered to arterioles locally to evoke conducted dilatory
responses. Measurements such as arteriolar dilation, distance of the conducted response
and conduction speed could therefore be quantified. Using sympathetic antagonists,
potential sympathetically-mediated restrictions of conducted responses can be
determined.
In addition to proposed sympathetically-mediated inhibition of conducted
vasodilation, the cellular components involved in the conducted dilatory response may
also be effected in pre-diabetes. The upward spread of dilation from distal arterioles is an
electrical event mediated by cell-to-cell coupling. Activation of endothelial potassium
channels leads to hyperpolarization of endothelial cells that is conducted along the vessel
and traverses into vascular smooth muscle cells via myoendothelial gap junctions
(Bagher & Segal, 2011). Interestingly, previous work has demonstrated that the activity
of ATP-sensitive potassium channels of gracilis feed arteries is augmented in obese
Zucker rats (Hodnett et al., 2008). These findings may be translated to the pre-diabetic
state, as obesity is commonly associated with pre-diabetes. This may cause impairments
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in the ability to initiate and sustain conducted dilatory responses throughout arteriolar
skeletal muscle networks. Whether expression and/or function of ion channels involved
in initiating vasodilatory hyperpolarization is augmented in pre-diabetes remains to be
investigated.
In chapter 2, expression of NPY was greater in hindlimb tissue of pre-diabetic rats
compared to control rats. Increased neurotransmitter (NT) expression of NPY supports an
increase in NT release and increased SNA reported to accompany hyperinsulinemia and
insulin resistance in pre-diabetes. Interestingly however, expression of hindlimb tissue
Y1R and α1R was also elevated. Conventionally, an increase in ligand causes
internalization and down regulation of receptors, but findings from chapter 2
demonstrated the opposite. Thus modification of sympathetic Y1R and α1R expression in
pre-diabetes may occur via epigenetic influences, despite the increased presence of NTs.
Pilot experiments were performed to investigate whether pre-diabetic conditions modify
receptor expression of vascular smooth muscle cell (VSMC) Y1R and α1R. Vascular
smooth muscle cells were isolated from aortas of both control and pre-diabetic mice and
cultured in vitro (see Appendix A for methods). Cultured VSMCs from control and prediabetic mice were then treated with media supplemented with glucose, insulin and leptin
at concentrations similar to physiological levels observed in pre-diabetic mice. Upon
Western blot analysis of Y1R and α1R VSMC protein expression, novel results indicated
that media mimicking ‘pre-diabetic conditions’ (high glucose, insulin and leptin) could
modify sympathetic receptor expression in VSMC of control mice and pre-diabetic mice
(Figure 5.1). Although data are preliminary, these novel findings may provide
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implications for initiation of sympathetic vascular dysregulation initiated early in prediabetes, as a result of pre-diabetic pathological characteristics.
In addition to the aforementioned directions of study, other factors contributing to
microvascular dysregulation in pre-diabetes may be considered. Investigation of
sympathetic vascular control mechanisms can be extended, where future experiments
may address β-adrenergic, as well as purinergic vascular modulation in pre-diabetes.
Also, studies may aim to determine whether increased sympathetic receptor expression
may be resolved spatially, where heterogeneous receptor distribution may be modified
along individual arteriolar segments within skeletal muscle. Furthermore, long-term
effects of heightened SNA may be reflected in changes of microvascular morphology, as
NPY possesses potent vascular mitogenic properties (Shigeri & Fujimoto, 1993).
Nonetheless, the ability to visualize the microvasculature is a powerful tool for
investigating modifications in vascular function in pre-diabetes. At this early stage in
diabetic disease progression, pathological modifications of vascular control mechanisms
can be resolved at the level of the resistance vasculature, and may translate to
microvascular complications in the human condition, which may not be resolved.
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Figure 5.1. Glucose, insulin and leptin modifies vascular smooth muscle cell Y1R
and α1R expression in CTRL and PD.
Protein expression of Y1R and α1R in aortic VSMCs isolated from control (CTRL n=26) and pre-diabetic (PD, n=2-6) mice. VSMCs were exposed to high glucose media (17
mM), low glucose media (5 mM), high insulin media (100 ng/mL), high leptin media (50
ng/mL), and high glucose, insulin and leptin DMEM (mimicking pre-diabetic
conditions). * different from PD high glucose, insulin and leptin condition; ** different
from PD high leptin condition, 1-way ANOVA. Data represent mean values of Western
blot band densities normalized to β-actin ± SEM.
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Appendices
Appendix A
i) Isolation and culture of vascular smooth muscle cells
At the end of a subset of experiments (n=4-6), the CTRL or PD animal was
euthanized and placed in the supine position. Under stereomicroscopic guidance and
using sterile surgical instruments, a midline incision of the chest was made through the
sternum to expose the chest cavity. Cardiac puncture was performed to remove blood
volume, followed by cardiac perfusion of 1 mL sterile Hanks buffered saline solution
(HBSS 1X, Invitrogen Canada Inc., Burlington, ON, Canada) through the apex of the
heart. The lungs were then removed to clearly visualize the heart and aorta. Excess fat
surrounding the proximal aorta was also removed. Two incisions were then made to
remove the aorta, one below the aortic arch and one above the diaphragm. The isolated
aorta was rinsed in HBSS and placed in enzymatic digestion solution (5% collagenase
type II [Worthington Biochemical, Lakewood, NJ, USA], 5% soybean trypsin inhibitor
[Invitrogen Canada Inc., Burlington, ON, Canada], 0.8 units/mL elastase [Worthington
Biochemical, Lakewood, NJ, USA], suspended in HBSS) at 37°C for 10 minutes. The
aorta was then moved to and rinsed in a petri dish containing warmed high glucose
Dulbecco’s minimal essential medium (DMEM), supplemented with 20% fetal bovine
serum (FBS) and 1% penicillin-streptomycin (Invitrogen Canada Inc., Burlington, ON,
Canada). The outer adventitial layer was carefully removed and the aorta was cut open
longitudinally. All remaining blood clots were removed and the endothelial layer was
removed by gently scraping the inside of the aorta with forceps. The aorta was then
moved to a dish containing fresh warmed DMEM and cut horizontally into pieces, then
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placed into enzymatic digestion solution for up to 2 hours, incubated at 37°C and 5%
carbon dioxide. Once the pieces of aorta were dissolved, the vascular smooth muscle cell
(VSMC) suspension was triturated with a glass pipette and equal volume of warmed
DMEM was added to the dish. Cells were collected at 1500 rpm, washed twice, plated
and left undisturbed for 5-7 days at 37°C and 5% carbon dioxide. Cells were washed with
HBSS and passaged using 0.25% trypsin-EDTA treatment for dissociation. After passage
3-5, cells were weaned to 10% FBS supplemented DMEM.
ii) Experimental conditions and Western Blot analysis of cultured VSMC
At passage 8, approximately 1 million cells from each group (i.e. CTRL and PD)
were plated into each well of a six well plate. Cells were cultured to approximately 90%
confluence, serum starved for 24 hours, and re-incubated with the following media
conditions for 48 hours (media was changed every 12 hours): high glucose DMEM (17
mM), low glucose DMEM (5 mM), high insulin DMEM (100 ng/mL), High leptin
DMEM (50 ng/mL), High glucose, insulin and leptin DMEM (mimicking pre-diabetic
conditions). After 48 hours, media was removed and cells were washed in ice cold HBSS
and then lysed in lysis buffer (T-PER Tissue Protein Extraction Reagent, Fisher Scientific
Company, Ottawa, ON, Canada) containing protease (104 mM AEBSF, 80 lM aprotinin,
2.1mM leupeptin, 3.6 mM bestatin, 1.5 mM pepstatin A and 1.4 mM E-64) and
phosphatase (Halt Phosphatase Inhibitor Cocktail) inhibitors. Cells were scraped and then
triturated with a pipette. Cell lysates were centrifuged for 15 min at 14,000 rpm at 4°C.
Supernatant was collected and stored at -80°C until protein concentration was
determined.
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A Bradford assay was performed to determine total protein concentration of
samples. Ten micrograms of protein from CTRL or PD samples were loaded on a 4–12%
gradient gel and separated by SDS-PAGE. After electrophoresis, proteins were
transferred at a constant voltage to polyvinylidene fluoride membranes. To determine
Y1R VSMC protein expression, membranes were blocked for 1 hour in 5% bovine serum
albumin (BSA) in Tris-Buffered Saline + Tween-20 (0.5%) (TTBS) at room temperature.
Membranes were then incubated in primary antibody specific to mouse NPY Y1R
(AbCam Inc., Cambridge, MA, USA) in 5% BSA in TTBS at a concentration of 1:1000
at 4°C overnight. Membranes were washed in TTBS then incubated in secondary
antibody conjugated to horseradish peroxidase (goat anti-rabbit IgG, 1:20000) in 2.5%
BSA in TTBS for 1 hr. To determine VSMC α1R protein expression, membranes were
blocked for 1 hour in 5% non-fat skim milk powder in TTBS at room temperature.
Membranes were incubated in primary antibody specific to mouse α1R (AbCam Inc.,
Cambridge, MA, USA) in 5% non-fat skim milk powder and Tris buffered saline (TBS)
for 1 hour at room temperature. Membranes were washed in TBS and incubated in
secondary antibody conjugated to horseradish peroxidase (goat anti-rabbit IgG, 1:20000)
in 2.5% BSA in TTBS for 1 hour. Y1R and α1R membranes were washed three times
and bands were detected using an Immun-Star WesternCVC chemiluminescent kit (BioRad, Hercules, CA, USA) and imaged with the ChemiDoc XRS System (Bio-Rad,
Hercules, CA, USA). Following imaging, membranes were immediately washed in
TTBS, stripped, and blocked in 5% BSA in TTBS for 1 hour at room temperature.
Membranes were washed in TTBS and incubated in primary antibody specific to β-actin
(loading control, anti-beta actin, rabbit polyclonal, Abcam, Cambridge, MA, USA) for 1
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hour at room temperature. Membranes were then washed in TTBS, incubated in
secondary antibody and imaged (as above). Densitometric band analysis was performed
with Quantity One 1-D Analysis Software (Bio-Rad, Hercules, CA, USA). Quantified
protein expression values were normalized to β-actin.
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Appendix B

AUP Number: 2012-018 PI Name: Jackson, Dwayne AUP Title: Microvascular
Function In Skeletal Muscle Approval Date: 08/08/2012
Official Notice of Animal Use Subcommittee (AUS) Approval: Your new Animal Use
Protocol (AUP) entitled "Microvascular Function In Skeletal Muscle" has been
APPROVED by the Animal Use Subcommittee of the University Council on Animal
Care. This approval, although valid for four years, and is subject to annual Protocol
Renewal.2012-018::1
1. This AUP number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this AUP number.
3. Purchases of animals other than through this system must be cleared through the ACVS
office. Health certificates will be required.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety
components (biosafety, radiation safety, general laboratory safety) comply with
institutional safety standards and have received all necessary approvals. Please consult
directly with your institutional safety officers.
Submitted by: Copeman, Laura on behalf of the Animal Use
Subcommittee University Council on Animal Care
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